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ABSTRACT 
Acute necrotizing pancreatitis (ANP) is a common gastrointestinal cause of 
emergency admissions in dogs and humans and can lead to a systemic 
inflammatory response syndrome resulting in multiple organ dysfunction syndrome. 
Among the various complications associated with ANP, acute lung injury (ALI) or its 
more severe form, acute respiratory distress syndrome (ARDS), are major 
contributors leading to high mortality rates associated with severe acute pancreatitis 
(AP) in human patients. The incidence of ALI/ARDS in ANP dogs is not well 
characterized. However, signs of respiratory complications have been reported 
clinically in dogs suffering from AP. The pathophysiology of ANP and its systemic 
complications in dogs and humans are not well understood. Most of the data related 
to AP comes from rodent models of AP, which may not always represent the true 
mechanisms occurring in the lungs of dogs or humans with ANP.  
I decided to undertake evaluation of pancreas and lungs from dogs (N=21) 
that died of ANP. The cases were selected through the search of the medical 
records of the Veterinary Medical Center of the Western College of Veterinary 
Medicine (WCVM). Six healthy SPCA dogs were used as controls. The histology of 
pancreas was first graded to record the range of ANP severities within dog cases 
included in this study. Then, characterization of lung inflammation was done with 
histological grading and qualitative analysis of immunohistochemical staining for von 
Willebrand Factor (vWF), Toll-Like Receptor-4 (TLR4), interleukin-6 (IL6), and 
inducible nitric oxide synthase (iNOS). Quantification of the recruitment of septal 
macrophages in the lungs, designated as pulmonary intravascular macrophages 
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(PIMs), in ANP dogs was achieved by counting the number of positive cells in 
alveolar septa using a macrophage antibody (MAC387). The results revealed that 
dogs suffering from ANP have variable lung inflammation, which was characterized 
by a significant infiltration of mononuclear phagocyte cells in the alveolar septa of all 
ANP dogs (median, 138; range 31-935) compared to control dogs (median: 1.5; 
range 0-16; p < 0.001), which suggested that PIMs are induced in ANP. In addition, 
robust staining for vWF in alveolar septal capillaries in lungs of ANP dogs suggested 
a strong microvascular inflammatory response. Finally, TLR4, IL6, and iNOS 
expression was increased in lungs of ANP dogs compared to control dogs.   
The second study was to investigate whether PIMs are induced in a mouse 
model of L-arginine-induced ANP. Therefore, lungs of L-arginine treated mice (n=7 
per time point) were evaluated at various time points (24 hours, 72 hours and 120 
hours) using histology and immunohistochemical staining for CD68 cells and vWF. 
Nine control mice were used. Counting of CD68-positive cells in the lungs of mice 
treated with L-arginine showed increased numbers of mononuclear phagocytes in 
alveolar septa at every time point (p<0.001). Also, the lung’s vasculature from L-
arginine-treated mice showed increased vWF staining.  
Taken together, the data showed that ANP in dogs caused significant 
recruitment of PIMs, increased expression of vWF, TLR4, IL-6, and iNOS 
suggesting presence of lung inflammation. The mouse model of L-arginine-induced 
ANP also showed recruitment of PIMs and increased vascular expression of vWF 
suggesting that this model may be relevant to study the mechanisms of PIMs 
recruitment and their functions in lung physiology associated with ANP. !
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CHAPTER 1: REVIEW OF LITERATURE 
1.1. Introduction 
Acute pancreatitis (AP) is an important gastrointestinal cause of hospital 
admissions both in humans (1) and dogs (2, 3). Mild AP is considered completely 
reversible with an uncomplicated recovery. However, when people and dogs suffer 
from severe AP, such as acute necrotizing pancreatitis (ANP), a systemic 
inflammatory response syndrome can occur leading to multiple organ dysfunction 
syndrome with high mortality rates. The reported mortality rates for dogs and people 
with AP are highly variable but range between 27-58% (2-5) and 30-50% 
respectively (6-9). Among all systemic complications that are associated with severe 
AP in humans, acute lung injury (ALI) or its more severe form acute respiratory 
distress syndrome (ARDS) are responsible for up to 60% of the mortality occurring 
in the first week of the disease (10, 11).  
The incidence of ALI in people suffering from AP reported in different 
retrospective studies varies with reported incidences being 18% (12), 20% (13), 
27.7% (14), and 42 % (15). In addition, a retrospective study analysing chest 
radiographs from people with ANP revealed that 46% of the cases had pleural 
effusion which correlated significantly to the mortality outcome (15-fold increase in 
the mortality rate) (13).There are two retrospective studies reviewing the medical 
records of dogs with AP which reported clinical evidence of dyspnea or tachypnea in 
4/61 dogs(7%)(2) in the first study and 18/80 dogs(23%) in the second (5).These 
data in the literature suggest that pulmonary complications associated with AP are 
more common in people than in dogs. 
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The pathophysiology underlying systemic complications during severe AP is 
not well understood explaining why there is still no specific treatment for this 
condition. Significant efforts have been made in the past decades to attempt to 
further understand the mechanisms leading to development of a systemic 
inflammatory response syndrome and particularly ALI. However, the majority of our 
knowledge comes from studies using rodent models of AP and very little is known 
about the specific mechanisms occurring in dogs with AP. There is, to my 
knowledge, no study describing the histopathology of ALI in a group of clinical cases 
of AP (or ANP) in dogs. There is only one case report published in 1995 where the 
lung histology of a single dog with ANP was evaluated (16). Therefore, in this study, 
the lungs of 21 dogs that died or were euthanized because of ANP were evaluated 
to characterize the presence of lung inflammation with a particular interest for the 
presence of pulmonary intravascular macrophages (PIMs). Secondly, a mouse 
model of ANP was used to assess the induction of PIMs upon ANP. 
 
1.2 Pancreatitis overview  
1.2.1 Pancreas physiology 
Before exploring the pathophysiology of AP, the basic pancreatic physiology 
must be understood. The pancreas is divided into an endocrine portion, involved in 
regulating glycaemia through the production of insulin and glucagon, and into an 
exocrine portion synthesizing large amounts of digestive enzymes, such as lipase, 
amylase, elastase, chymotrypsinogen, and trypsin, which are stored in inactive 
forms in zymogen granules in the cytoplasm of acinar cells (17, 18). The exocrine 
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pancreas is composed of pancreatic acinar cells whereas the endocrine portion 
consists of clusters of different cell types forming islets of Langerhans dispersed 
throughout the exocrine portion.  Under normal circumstances, the pancreas 
secretes its inactive zymogens in the duodenum lumen where they become 
activated to participate in digestion (17). Furthermore, it is important to note that, as 
with other organs present in the peritoneal cavity, the venous effluent blood leaving 
the pancreas drains into the portal vein before reaching the systemic circulation (17). 
 
1.2.2 Pancreatitis definition and classification 
The term pancreatitis refers to the inflammation of the exocrine portion of the 
pancreas. Typically, the islets of Langerhans remain intact. Pancreatitis can be 
acute or chronic depending on the initial cause and the progression of the disease 
and can be classified based on either the histopathology (pathological classification) 
or the clinical severity of the disease (clinical classification) (3). At the moment there 
is no standardized, universally accepted classification for AP in human or veterinary 
medicine. The well-known Atlanta Classification of Acute Pancreatitis established in 
1992 has now become out-dated with the improvement of our clinical ability to 
diagnose the disease, and several new revised classification systems have been 
proposed recently (2, 3, 19, 20). Nevertheless, it seems appropriate to divide AP 
based on the presence or absence of pancreatic necrosis (14). Currently, a mild 
form with absence of pancreatic necrosis called interstitial edematous pancreatitis in 
human medicine (14) or edematous pancreatic inflammation in veterinary medicine 
(2) and a severe form characterized by pancreatic necrosis named acute necrotizing 
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pancreatitis in veterinary medicine are recognized (3). Most cases of AP in people 
are interstitial edematous pancreatitis (80-90%) whereas dogs are mainly diagnosed 
with ANP (2, 11, 21).  
 
1.2.3 Pancreatitis aetiology   
In people, gall stones are the most common cause of AP followed by alcohol 
consumption. Other less common causes or risk factors include endoscopic 
retrograde cholangiopancreatography, some form of drugs, obesity, diet, 
autoimmune diseases, pancreatic duct obstruction, and hyper-triglyceridemia (1). 
Often, the cause of AP in dogs cannot be determined but reported aetiologies 
include hyperlipoproteinemia, drugs (azathioprine, chlorthiazide, potassium bromide, 
sulfonamides, cisplatin, L-asparaginase, clomipramine), zinc intoxication, 
hypercalcemia, pancreatic duct obstruction, abdominal surgery, duodenal/biliary 
reflux, trauma, ischemia-reperfusion, and more (3). There is also a controversial 
anecdotal association between feeding high-fat, low-protein food or unusual food to 
dogs and the development of AP (22, 23).  In addition, hereditary pancreatitis has 
been characterized in humans and in Miniature Schnauzer dogs. In humans, five 
pancreatitis susceptibility genes have been identified and mutations in those genes 
are associated with increased trypsinogen activation (24-28). In Miniature 
Schnauzer dogs, three variations in the SPINK1 gene have been associated with 
the development of AP in this breed (29). In addition, hypertriglyceridemia is 
suspected to be involved in the development of AP in Miniature Schnauzer dogs!(30).  
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1.2.4.  Acute pancreatitis diagnosis 
Acute pancreatitis can be diagnosed with a combination of clinical 
assessments. However, the definitive diagnosis is confirmed by histological 
evaluation of the pancreas. Briefly, the clinical diagnosis of AP is based on the 
typical clinical signs (acute pain in the cranial abdomen, vomiting, anorexia, 
depression) (3), blood work and imaging methods including transabdominal 
ultrasonography, radiography and contrast-enhanced computed tomography (13). 
Serum amylase and lipase activities have been long used to assess the integrity of 
the pancreas. However, assessing the elevation of those enzymes is not a sensitive 
method and is not specific to pancreatic injury(3). There are now commercial kits 
measuring specifically canine pancreatic lipase (snap-cPLi or spec-cPL), which have 
higher specificity and sensitivity than evaluating lipase and amylase activities, but 
the sensitivity and specificity of those kits vary importantly between studies (31) (3). 
Canine trypsin-like immunoreactivity is thought to be specific for pancreatic injury 
but it can also increase during renal failure. It was shown to increase early in the 
course of AP, followed by a rapid decrease and therefore it’s level is often back to 
normal values when the patient is presented at the clinic (32-34).  
The definitive diagnosis of ANP is based on the presence of the following 
pancreatic lesions on histological evaluation: 1) acinar cell necrosis 2) 
peripancreatic fat necrosis 3) infiltration of inflammatory cells (neutrophils, 
mononuclear cells, lymphocytes or mixed) 4) pancreatic edema, and 5) 
haemorrhage (35, 36). Researchers have used various histological scoring systems 
to diagnose and grade the severity of AP in dogs (35-37).  
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1.3 Acute pancreatitis pathophysiology 
The pathophysiology of ANP in dogs is not well established and our current 
understanding of this disease is mainly extrapolated from rodent models of AP. 
There are various rat and mouse models of AP and all of them are associated with 
varying degrees of severity, induction pathophysiology, and pathways leading to 
systemic complications. Unfortunately, we do not know which experimental model 
resembles most closely to the mechanisms naturally occurring in dogs suffering 
from ANP. The review of literature also reveals the challenges of comparing results 
from various models of ANP.  There have been a few studies using dog models of 
AP for diagnosis or treatment purposes but not to describe the pathophysiology of 
the disease in dogs (38).  
The most common and important rodent models of AP include: 1) 
administration of cholecystokinin (CCK) analog (cerulein) resulting in a mild 
pancreatitis 2) a dietary model with a choline-deficient diet causing ANP 3) 
administration of L-arginine intraperitoneally (IP) inducing ANP and 4) retrograde 
injection of sodium taurocholate in the bileopancreatic duct causing severe 
hemorrhagic necrotizing pancreatitis (39, 40). Many other models exist but are less 
commonly used (39, 40). 
The development of ANP is the result of various mechanisms including 
premature activation of digestive enzymes within pancreatic acinar cells, activation 
of inflammatory pathways, altered pancreatic microcirculation, oxidative stress, 
activation of the complement system, and potentially the kallin-kallikrein and renin-
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angiotensin systems (28). A description of the main mechanisms involved in ANP is 
described here. 
 
1.3.1 Trypsin-centered theory  
In 1896, Chiari proposed the trypsin-centered theory of pancreatitis stipulating 
that pancreatitis is initiated by intra-acinar premature activation of trypsinogen into 
trypsin leading to autodigestion of the pancreas. It is well accepted that during 
pancreatitis, zymogen granules containing trypsinogen are not normally secreted 
into the duodenum lumen but instead are fused with lysozymes containing 
lysosomal proteases such as cathepsin B, which activates trypsinogen into trypsin 
(41-49). It is believed that a secretory block occurs on the apical surface of acinar 
cells preventing zymogen granules from exiting the cells (50). The activated trypsin 
can then cause the activation of other digestive enzymes present in acinar cells 
leading to further pancreatic injury. To protect themselves against activated trypsin, 
acinar cells are equipped with protective mechanisms including pancreatic secretory 
trypsin inhibitors (PSTI) and the induction of rapid cell death through zymophagy (17, 
41). However, those mechanisms become quickly overwhelmed during AP resulting 
in the accumulation of trypsin causing acinar cell death through apoptosis or 
necrosis. According to this theory, the autodigestion of acinar cells causes the 
release of the cytoplasmic content of necrotic cells and activates inflammatory 
pathways in the pancreas promoting local inflammation (17, 18).  
The trypsin-centered theory has been the basis of our understanding of AP 
for the last century (18). However, in the last decades, studies using genetically 
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modified rodents lacking trypsinogen or cathepsin B have suggested that trypsin-
independent mechanisms can lead to acinar cell necrosis and to the development of 
AP (42, 51).  Therefore, the biological significance of the premature activation of 
pancreatic digestive enzymes is being questioned.  Some studies even suggest that 
intra-acinar premature activation of trypsinogen may be a protective defense 
mechanism in the early stage of pancreatitis in order to limit the activation of more 
digestive enzymes (44, 52-55). 
 
1.3.2 Pancreatic inflammation 
During AP, a substantial amount of pro-inflammatory mediators are released 
into the systemic circulation from the injured pancreas. Both pancreatic acinar cells 
and inflammatory cells are involved in the inflammation component of AP. Activation 
of NF-κB signalling pathways in pancreatic acinar cells has been shown to be one of 
the earlier events to occur during the initiation of AP in various experimental models 
(56, 57). The activation of NF-κB leads to the production of Tumor-necrosis-factor-α 
(TFNα) and interleukin (IL)-1β, which are the first pro-inflammatory cytokines to 
increase during AP (58, 59). Together, TNFα and IL-1β promote pancreatic 
inflammation by increasing the expression of ICAM-1 on endothelial cells and 
stimulating the production of interleukin-8 (IL-8), which leads to the recruitment and 
migration of neutrophils into the pancreas (60, 61). IL-6, another important pro-
inflammatory cytokine, is also increased during AP and this cytokine, along with IL-8, 
is correlated to the severity of AP (62, 63). Other pro-inflammatory cytokines 
investigated during AP include IL-2, IL-4, IL-11, and IL-18.  
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Neutrophils are the first inflammatory cells to be recruited into the pancreas 
during AP and their depletion decreases the severity of the disease confirming their 
role in causing pancreatic injury (64, 65). In addition to being recruited via NF-κB 
signalling pathways, pancreatic enzymes such as trypsin, elastase, and 
chymotrypsin are able to regulate the migration of neutrophils during AP by 
increasing the expression of ICAM-1 on neutrophils and endothelial cells (66, 67). 
Neutrophils can then cause pancreatic injury through the release of their granules 
containing reactive oxygen species (ROS) such as superoxide (O2-), hydrogen 
peroxide (H2O2), and hydroxyl ions (OH-) (66). Neutrophils could also have 
modulatory roles during AP as they cause a shift from acinar cell apoptosis to 
necrosis during AP (64, 68). Monocytes are also recruited to the pancreas during AP 
via MCP-1 and the administration of an MCP-1 blocker reduced the severity of AP 
(69). The question whether the activation of NF-κB and development of inflammation 
is a consequence of trypsinogen activation or whether inflammation in the pancreas 
occurs independently of the activation of trypsin is not settled as contradictory 
results have been obtained (42, 70, 71).  
 
1.3.3 Nitric oxide and oxidative stress 
The role of nitric oxide (NO) and oxidative stress in AP is controversial. NO is 
known to participate in pancreatic physiology by regulating pancreatic exocrine 
secretion, promoting capillary integrity, inhibiting leukocyte adhesion, and 
modulating the pancreatic microvascular blood flow (72, 73). However, in 
experimental pancreatitis, contradictory roles for NO have been shown as it 
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increased oxidative stress causing hypotension (74, 75) or had protective effects via 
increasing the blood flow (76). ANP and high mortality rate have been associated 
with vasoconstriction in pancreas in animals and humans (77-79). It was also 
suggested that the vascular endothelium nitric oxide synthase would be protective 
during AP but the inducible nitric oxide synthase (iNOS) expressed by macrophages 
is associated with more severe AP. A recent study showed that the severity of AP 
was correlated to plasma NO and that oxidative stress was greater in people 
developing systemic complications (80). 
 
1.4 Acute lung injury and acute respiratory distress syndrome 
Acute inflammation is typically characterized by vasodilation, increased blood 
flow, increased vascular permeability leading to accumulation of fluid exudates and 
migration of leukocytes, and the activation of nociceptors. These physiological 
events lead to the classical cardinal signs of inflammation: pain, swelling, redness, 
heat, and loss of function. The fundamental role of inflammation is to protect the 
body against various threats such as pathogens (virus, bacteria, fungi, parasite), 
tissue injuries (burns, trauma, necrosis), toxic substances and foreign bodies. In 
most of the cases, inflammation is beneficial and allows the restoration of 
homeostasis. However, in some conditions, the inflammatory response can become 
excessive or prolonged resulting in more tissue damage and loss of physiological 
functions. Examples of conditions where the inflammation itself becomes detrimental 
for the host include, among others, ALI, allergic reactions, autoimmune diseases, 
intestinal bowel disease, organ transplantation, and cancer. 
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ALI and its more severe form ARDS are two common and devastating 
syndromes associated with high mortality and morbidity, both in human and 
veterinary patients. In 1993, the American-European Consensus Committee (AECC) 
established criteria to diagnose ALI and ARDS in human patients providing 
consistent definitions and nomenclature. The AECC defines ALI as follow: 1) acute 
onset 2) presence of hypoxemia (PaO2/FiO2 < 300mm Hg) 3) diffuse bilateral 
pulmonary edema seen on frontal radiographs, and 4) pulmonary artery occlusion 
pressure ≤ 18mm Hg, or no evidence of left atrial hypertension (81). ARDS is 
characterized by the same criteria but with more severe hypoxemia (PaO2/FiO2 < 
200mm Hg).  In 2007, more appropriate definitions of ALI and ARDS for veterinary 
medicine were established dividing ALI into 3 main definitions: 1) Neonatal equine 
respiratory distress syndrome (NERDS), 2) veterinary ALI and ARDS (VetALI/ 
VetARDS) and 3) equine neonatal ALI/ARDS (EqNALI/ EqNARDS)(225).  
The pathophysiology of ALI is complex and involves two main responses: a 
vascular and a cellular response. ALI can be direct (or primary) when the aggressor 
enters the lungs via the airways such as in microbial pneumonia, aspiration 
pneumonia and smoke/toxic gas inhalation. ALI can also be indirect (or secondary) 
when the inflammatory stimuli reach the lungs via the blood circulation as in AP, 
sepsis, endotoxemia, severe burns, blood poisoning, and disseminated intravascular 
coagulation (DIC) (82). Indirect ALI is initiated by a vascular response where 
structural changes in the microvasculature of the lungs are induced by inflammatory 
stimuli present in the blood circulation. This leads to increased vascular permeability, 
expression of adhesion molecules on endothelial cells and production of 
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chemokines resulting in the recruitment and migration of leukocytes into the lungs 
(83). Neutrophils are typically the first inflammatory cells to be recruited in the lungs 
during ALI and are highly efficient in clearing pathogens (83). However, excessive 
infiltration of neutrophils in the lungs can be harmful as they cause further tissue 
injury via release of their granules content, such as reactive oxygen species (ROS) 
and proteases (78). Histologically, those changes result in interstitial and alveolar 
edema, vascular congestion, infiltration of inflammatory cells typically neutrophils 
into the lung parenchyma and alveolar spaces, thickening of alveolar septa, and, in 
some cases, haemorrhages (84, 85). 
The cellular response during ALI is strongly modulated by resident lung 
macrophages including alveolar macrophages, interstitial macrophages and in some 
cases pulmonary intravascular macrophages (PIMs). Alveolar macrophages reside 
in the alveoli and constitute the first line of defense against inhaled threats reaching 
the alveoli whereas interstitial macrophages are present in the interstitial space 
between the alveolar epithelium and the vascular endothelium (86). In some species, 
monocytes present in the microvasculature of the lungs have been shown to adhere 
to the endothelium and differentiate in a third population of macrophages called 
PIMs (87).  The potential roles of PIMs in lung inflammation will be discussed later in 
section 1.4.1.  
Macrophages are highly versatile cells and can adopt pro-inflammatory (M1 
or classically activated) or anti-inflammatory phenotypes (M2 or alternatively 
activated) (88). M2 macrophages can be further divided into wound-healing (M2a) or 
regulatory (M2b) macrophages.(89). The development of one phenotype over the 
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other depends on the balance between activating and repressing signals present in 
the local environment. Alveolar macrophages have been assigned both pro-
inflammatory (M1) and regulatory (M2) phenotypes during inflammatory settings (90). The induction of a pro-inflammatory (M1) phenotype is mediated by 
inflammatory cytokines including interleukin (IL)-1, interferon (IFN), TNFα and 
through activation of pattern recognition receptors (PRRs), such as Toll-like 
receptor-4 (TLR4) by lipopolysaccharide (LPS) (91). Pro-inflammatory macrophages 
have essential roles in the host defense against pathogens via enhanced 
phagocytosis of microorganisms and antigen-presentation. However, they are also 
associated with enhanced production of matrix metalloproteinases and upregulation 
of iNOS leading to the production of NO and ROS, which can have detrimental 
consequences for the host in addition to killing microbes (89, 92). Also, M1 
macrophages produce pro-inflammatory cytokines and chemokines including TNFα, 
IL1β, IL6, IL8, IFNγ, and IL12, which induce neutrophil and monocyte recruitment 
(93). Interstitial macrophages would have a regulatory phenotype (M2b) by 
producing anti-inflammatory cytokines such as IL-10, which inhibit immune response 
and inflammatory processes (94, 95).   
 
1.4.1 Pulmonary intravascular macrophages (PIMs) 
There are now various studies showing that lungs from some species 
possess a third type of constitutive macrophages called pulmonary intravascular 
macrophages (PIMs). As the name suggests, PIMs are mature macrophages rather 
than monocytes and are located in the microvasculature of the lungs, mainly in the 
! 14!
thick portions of alveolar septa. In sheep, PIMs were shown to cover up to 20% of 
the lung endothelium surface (96, 97). Briefly, PIMs are highly phagocytic large cells 
(20-80 µm diameter) proven to be firmly attached to lung endothelial cells and are 
believed to have pro-inflammatory functions.  
Species in the orders Artiodactyla (cattle, water buffalos, sheep, goats and 
pigs) (97-104), Perissodactyla (horses) (105-107), Odontoceti cetacean (toothed 
whales) (108) and some strains of domestic cat (109) have been shown to have  
constitutive PIMs, which colonize the lungs early after birth (96, 97).  Species 
included in the order Rodentia (rats, mice, guinea pigs, hamsters) (101, 110) do not 
have constitutive PIMs. However, studies using rats have shown that PIMs can be 
induced (induced PIMs) upon physiological stress such as endotoxemia and liver 
dysfunction (111, 112). Although the mechanisms by which PIMs are induced 
remain to be understood, it is suggested that their induction is mediated through 
altered pulmonary endothelium leading to the production of chemokines and 
adhesion molecules.    
Few studies have been conducted to evaluate the extent of PIMs in humans 
and dogs. Only one ultrastructural report has been published showing very few PIMs 
in the human lung leading to the suggestion that human lungs do not normally have 
PIMs (113). In addition, older publications have indirectly shown that PIMs could be 
induced during liver dysfunction in humans, resembling to what was observed in 
other species devoid of constitutive PIMs (114-117).  Two studies assessed the 
presence of PIMs in normal dogs but none succeeded to prove their existence 
leading to the proposition that dogs normally do not contain constitutive PIMs (118). 
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Furthermore, in a fairly recent study (2008), the presence of PIMs in 2 normal dogs 
and 2 dogs receiving a transplant of dead Dirofilaria immitis was evaluated and the 
results revealed an absence of constitutive or induced PIMs in those dogs (119). 
Furthermore, a recent (2011) immunohistochemical study using 2 dogs was 
performed previously in our laboratory and showed presence of few mononuclear 
phagocytes in alveolar septa (120). To my knowledge there are no studies that have 
assessed the induction of PIMs in a larger group of dogs suffering from lung injury. 
PIMs have a robust and very efficient phagocytic capacity for particles 
present in the blood circulation, including viruses, bacteria, LPS, cellular debris, and 
effete erythrocytes (112, 121-125). As the pulmonary circulation receives the entire 
cardiac output, PIMs are thought to play a physiological role in the clearance of 
blood particles, similar to the liver and spleen intravascular macrophage system 
(126, 127). However, because of their ability to clear and process microorganisms 
and antigens, PIMs may constitute a potential reservoir of infectious agent in the 
lungs with a potential detrimental impact on the lung health. 
Our knowledge of PIMs’ contribution to lung inflammation mainly comes from 
in vivo studies where PIMs were either induced in species that lacked these cells or 
were depleted with gadolinium chloride or clodronate lipososmes in species with 
constitutive PIMs (111, 112, 128-132). Protective effects of PIMs’ depletion were 
noted in various models of ALI in species with constitutive PIMs such as in 
endotoxin-mediated lung injury in sheep (131) and horses (106), and in calves 
infected with Mannheimia hemolytica (130), thus attributing a pro-inflammatory role 
to PIMs. Overall, depletion of PIMs in those species resulted into reduced lung 
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levels of pro-inflammatory cytokines and chemokines, improved lung histology and 
reduced migration of inflammatory cells. Also, recent data show that depletion of 
PIMs in horses with spontaneous heaves led to a reduction in clinical signs and 
reduction in migration of neutrophils into the lungs(87).   
It has been observed that species with constitutive PIMs, such as horses 
(128), sheep (131) or cattle (130) develop more severe lung inflammation following 
endotoxemia compared to species without constitutive PIMs, such as rats, where 
higher doses of LPS are needed to induce ALI (101, 111, 130, 133). However, lungs 
from rats with induced PIMs, including the bile duct-ligated rat model (111), the rat E. 
coli sepsis model (112), the rat hepatopulmonary syndrome model (111, 132), 
become sensitive to very low dosages of LPS (dose in µg/kg instead of mg/kg) (111) 
and the lung inflammatory response thus induced is more intense compared to 
control rats receiving their first LPS challenge. However, when PIMs are depleted 
after their induction in rats, the lung inflammatory response is reduced (111). 
Pro-inflammatory signalling pathways in PIMs are suggested to occur through 
TLRs, such as TLR-4, TLR-9, and TLR-2 during sepsis and endotoxemia (111, 134-
136). Following activation of TLRs, PIMs produce large amounts of pro-inflammatory 
mediators such as TNF-α (137), IL-1β and iNOS products (111) (130, 138), which 
can stimulate local endothelial cells or cross alveolar septa and stimulate alveolar 
macrophages (111, 134-136). Histologically, PIMs’ stimulation is associated with 
vascular congestion and recruitment of inflammatory cells (137). PIMs’ activation 
was also linked to aggregation of IL-8-rich platelets in the lungs in calves challenged 
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with intra-tracheal Mannheimia hemolytica, which may promote the recruitment of 
neutrophils (130).  
Taken together, studies on PIMs suggest that they are pro-inflammatory and 
that their stimulation or induction enhances the lung susceptibility for the 
development of an enhanced inflammatory response to microbial challenges, which 
could lead to respiratory distress and have detrimental consequences for the host. 
However, the contribution of induced PIMs in lung physiology and in pathologic 
settings remains to be further characterized and accepted.   
 
1.5 ALI associated with acute pancreatitis 
Significant efforts have been made in the last decades to attempt to describe 
the mechanisms initiating and maintaining lung inflammation during AP. But there 
are still significant gaps in our comprehension of AP-associated lung 
pathophysiology. ALI is multifactorial and results from a complex combination of the 
release of pancreatic-specific proteins, activation of Kupffer cells and peritoneal 
macrophages, gut barrier dysfunction and the activation of alveolar macrophages in 
the lungs. A summary of the pathophysiology of AP-associated ALI follows. 
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1.5.1 Extra-pulmonary mechanisms involved in ALI associated with 
acute pancreatitis 
1.5.1.1 Kupffer cells  
It has been clinically observed that people suffering from pancreatitis 
associated with pancreatic transplantation demonstrate reduced (or absent) signs of 
systemic complications, including ALI, as opposite to what is seen during naïve 
pancreatitis (139, 140). During pancreatic grafting, the pancreatic venous effluent 
blood is drained into the iliac veins (systemic circulation) instead of into the portal 
vein, therefore, by-passing the liver. This led to the hypothesis that the liver plays a 
key role in the pathophysiology of systemic inflammatory response syndrome and 
ALI during acute pancreatitis.  
Similar protective effects on ALI were noted in rodent models where a porto-
caval shunting to prevent the passage of blood from the pancreas to the liver was 
performed or when gadolinium chloride was used to deplete Kupffer cells before the 
induction of AP (141). Kupffer cells are mononuclear phagocytes present in the 
microvasculature of liver and therefore get exposed to various pro-inflammatory 
mediators, including pancreatic enzymes such as elastase, released by the inflamed 
pancreas during AP (142). Either the porto-caval shunting or depletion of Kupffer 
cells abolished the rise of systemic pro-inflammatory molecules such as IL-6, TNFα, 
IL-1β and HSP-72 and protected against ALI (143-146). Reduction of ALI following 
those procedures was characterized by reduced recruitment of neutrophils in the 
lung assessed by myeloperoxidase (MPO) activity, lower histology scores, decrease 
of NF-kB activation in alveolar macrophages and lower production of NO, TNFα and 
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MIP-2 by alveolar macrophages (143, 146, 147). It is important to note that 
gadolinium chloride may deplete other macrophages such as those in the spleen in 
the host, which makes it challenging to directly assess the contributions of Kupffer 
cells in ALI associated with AP.  
 
1.5.1.2 Peritoneal macrophages  
The peritoneal cavity possesses inflammatory cells mainly macrophages and 
neutrophils, as a major line of defense against infection of the abdominal cavity. 
There are data to show an increase in the numbers of peritoneal macrophages 
during AP, and these macrophages contribute to the development of systemic 
inflammatory response syndrome and ALI upon activation by trypsin (148). People 
suffering from AP have been shown to have leakage of trypsin (149) and trypsin 
activation peptide (150) into their peritoneal cavity. Indeed, activated pancreatic 
enzymes can leak through the basolateral membrane of acinar cells accumulating in 
the pancreatic interstitium and peri-pancreatic tissue and then access the peritoneal 
cavity (150).  
Using in vitro culture techniques, activation of peritoneal macrophages by 
trypsin led to the production of TNFα and IL-1β in a dose-dependent manner (151). 
TNFα and IL-1β are both found to be elevated in ascitic fluid of various rodent 
models of severe pancreatitis (148). The injection of trypsin into the peritoneal cavity 
of rats increased levels of ascites TNFα in conjunction with lung inflammation (151) 
suggesting that the activation of peritoneal macrophages by trypsin may contribute 
to the development of ALI. Furthermore, performing peritoneal lavages with 
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protease inhibitors in AP rats decreased the level of lung injury (152) or had no 
effect (153). Similarly, depletion of peritoneal macrophages by intravenous injection 
of liposome-encapsulated dichloromethylene bisphosphonate (Cl2MBP liposomes) 
in ANP rats decreased the levels of pro-inflammatory cytokines in the peritoneal 
lavage (TNFα and IL-1β) and in the serum (IL-6 and IL-8), and protected against 
lung inflammation shown by reduced infiltration of neutrophils and edema on 
histological evaluation and reduced MPO activity (154). However, the intravenous 
treatment to deplete peritoneal macrophages may have also affected Kupffer cells. 
Peritoneal macrophages isolated from AP rats also expressed increased levels of 
iNOS, which suggests their role in raising the level of NO in the systemic circulation 
during AP(155). 
 
1.5.1.3 Pancreatic enzymes 
During AP, trypsin, elastase and phospholipase A2 (PLA2) are released in the 
blood circulation from the injured pancreas (149). Trypsin has been shown to cause 
vascular injury to various organs during AP including the lungs (156, 157). In 
addition, PLA2 can cause surfactant degradation as well as increased vascular 
permeability via cell membrane phospholipid hydrolysis (158). Elastase can cause 
degradation of elastin in blood vessel walls and chymotrypsin activates xanthine 
oxidase leading to oxidative damage. Therefore, the release of pancreatic enzymes 
into the systemic circulation during AP can potentially cause vascular injury in the 
lungs promoting inflammation. 
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1.5.2 Lung mechanisms involved in ALI associated with AP 
1.5.2.1 Neutrophils  
Neutrophil recruitment occurs early in the course of lung inflammation during 
experimental AP and is associated with tissue damage such as vascular injury 
leading to increased vascular permeability (64, 156, 159). Depletion of circulating 
neutrophils with specific antibodies in various experimental AP studies prevented 
lung vascular permeability, decreased lung weight, improved histological scores, 
and increased the survival rate (64, 159, 160). However, in some models of AP, the 
severity of pancreatitis was also reduced when circulating neutrophils were depleted, 
which could therefore indirectly have a protective effect on lung injury (64, 159).   
Neutrophil recruitment in the lungs seems to depend on the expression of 
intercellular adhesion molecule 1(ICAM-1) (67, 161). Humans suffering from ANP 
had higher levels of ICAM-1 in their plasma, which was correlated with the severity 
of AP (162). In addition, pulmonary expression of ICAM-1 is increased during 
experimental pancreatitis and was associated with the infiltration of neutrophils into 
the lungs (67, 163). Other mechanisms believed to be involved in ALI mediated by 
neutrophils include the activation of complement (159) and injury via hydrogen 
peroxide (H2O2) released from neutrophil granules. 
It is not clear whether neutrophils are previously activated in the inflamed 
pancreas and then reach the lungs via the systemic circulation or if they are being 
recruited to the lung by activated endothelial cells or alveolar macrophages. 
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1.5.2.2 Pulmonary alveolar and interstitial macrophages  
Many studies have focused on the role of alveolar macrophages in ALI 
associated with AP. As mentioned previously, pro-inflammatory mediators released 
by activated peritoneal macrophages and Kupffer cells in the early course of AP can 
lead to the activation of AM. In addition, there is some evidence that alveolar 
macrophages can also be activated by pancreatic-specific proteins such as PLA2, 
which is found to be elevated in the serum and BAL fluid of humans with AP 
complicated with ALI (164-169).  
Activated alveolar macrophages during AP have been shown to acquire a 
pro-inflammatory phenotype (M1) producing pro-inflammatory mediators such as 
TNFα, IL-1β, and MIP-2 resulting in the recruitment neutrophils into the lungs (147, 
164, 170-172). In addition, a great amount of work has been done regarding the 
induction of iNOS in alveolar macrophages and the production of NO in the lungs 
during AP. Alveolar macrophages have been shown to express high levels of iNOS 
in various experimental AP studies resulting in increased levels of NO in the lungs 
(164, 171, 173). iNOS in alveolar macrophages was reported to be induced by 
pancreatic PLA2 both in in vitro and in vivo experiments (147, 164, 171, 172).  The 
role of NO during ALI associated with AP is controversial as in some studies the 
increase in NO has been associated with more lung injury (164, 173) whereas in 
other studies NO was protective and reduced the severity of ALI (174).  In one of the 
AP studies, interstitial macrophages were characterized by an inhibitory phenotype 
(M2b) as they produced anti-inflammatory cytokine IL-10 through PPARgama 
activation (170).  
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1.5.2.3 Innate immunity: Lung TLRs 
TLRs are part of the pattern recognition receptors (PRRs) family and have 
critical roles in the host defense against invading microorganism via the recognition 
of pathogen-associated molecular pattern (PAMP) of viruses, bacteria and fungi by 
immune cells (175).  Activation of TLRs leads to a series of signalling pathways 
causing an acute response necessary to kill pathogens. TLR4 is a well-known 
receptor for LPS and is involved in bacterial infections and septicemia caused by 
Gram-negative bacteria (176, 177). However, it has been shown that TLR4 can also 
be activated in settings other than LPS or other bacterial products by recognizing 
damage associated molecular pattern molecules (DAMPs) such as heat shock 
protein 60 and 70, extra domain A of fibronectin, oligosaccharides of hyaluronic acid 
and fibrinogen (178, 179). Although TLR4 is involved in protecting the host against 
various infections, over-expression of this receptor can lead to the production of an 
excessive amount of pro-inflammatory cytokines and subsequently to undesirable 
tissue damage. TLR4 could be involved in ALI associated with AP since sepsis and 
endotoxemia are potential complications. 
It has been shown in rats that acute hemorrhagic necrotizing pancreatitis 
leads to an increased expression of TLR4 in the lungs assessed by mRNA and 
protein expression and was associated with lung injury (174). The increased TLR4 
in the lungs of those rats was associated with the production of increased level of 
IL6 and TNFα and with histological signs of lung injury. Therefore, it was suggested 
that TLR4 may have a role in the development of ALI associated with severe AP. 
However, the identity of cells contributing to increased TLR4 in the lungs and 
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whether this increase is mediated via endotoxemia are not fully understood.  
 
1.6. L-arginine-induced mouse ANP model 
In 1984, it was observed that a high dose of L-arginine injected 
intraperitoneally induces changes in the pancreas consistent with acute pancreatitis 
(180). Since then, intraperitoneal injections of an L-arginine solution have been used 
in rats to induce ANP while sparing the islets of Langerhans and without causing 
injury to other abdominal organs (180-182). However, it is only since 2007 that the 
L-arginine procedure to induce ANP has been standardized in mice (181). The 
pancreatitis induced in mice with L-arginine is characterized histologically by 
changes in the pancreatic acinar cells as early as 6 hours with disappearance of 
zymogen granules from some areas after 24 hours followed by the appearance of 
inflammatory cells and acinar cell necrosis at 72 hours and with only small areas of 
intact acinar cells remaining after 96-120 hours (181). In addition, plasma amylase 
levels rise within 24-48 hours, peak at 72 hours and return to normal values within 
96-120 hours following L-arginine treatments (181, 183).  This non-invasive model is 
associated with a low mortality rate and is considered a physiologically good model 
to study the progression of AP as well as its systemic complications including ALI. In 
mice, ALI is characterised histologically by alveolar thickening, infiltration of 
inflammatory cells mainly neutrophils and pulmonary hemorrhage at 72 hours after 
the L-arginine challenge, and this is associated with increased lung MPO activity 
(181, 184, 185). In addition, interestingly, there has been a case report of a 16 years 
old boy diagnosed with acute pancreatitis which was associated to the boy’s daily 
! 25!
intake of L-arginine supplements (500 mg/day) over a period of 5 months for the 
purpose of body building (227). 
 
1.6.1 L-arginine-induced ANP model mechanisms  
The pathophysiology of the L-arginine-induced ANP model is not fully 
understood. L-arginine is classified as a conditionally essential amino acid and can 
be metabolised by two main enzymes: arginase and nitric oxide synthase. It is 
mostly accepted that the arginase metabolism pathway is involved to some degree 
in the pathophysiology of this model. However, discrepancy exists regarding the role 
of nitric oxide synthase and NO in the induction of pancreatitis.  
Arginase is mainly present in the liver and is a key enzyme in the urea cycle 
as it hydrolyses L-arginine into L-ornithine and urea. Because very little arginase is 
present in the pancreas, kidneys and lung, most of L-arginine is believed to be 
metabolized in the liver (186). A pharmacokinetic study of L-arginine administered 
intraperitoneally suggested that the half-life of L-arginine is between 1-2 hours, 
indicating that L-arginine is rapidly metabolized (180). It was shown that, after 
intraperitoneal injections of L-arginine, the levels of L-ornithine increased by a 54-
fold indicating the importance of this pathway in metabolising L-arginine in this 
model (187). The role of the arginase pathway in the development of pancreatitis 
was demonstrated by the inhibition of this enzyme prior to L-arginine injections, 
which reduced pancreatitis severity by decreasing trypsin level, pancreatic MPO 
activity, and histology scores (186). Furthermore, it is L-arginine’s metabolite L-
ornithine, rather than L-arginine itself, that is believed to induce pancreatic injury. 
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Intraperitoneal injections of L-ornithine create ANP at lower doses than L-arginine 
(187). More specifically, L-ornithine would generate free radicals such as superoxide 
and thus have toxic effects via oxidative stress (188, 189).  
Nitric oxide synthase, which is present in pancreatic acinar cells (190), 
metabolises L-arginine into L-citrulline and NO. An increase in iNOS has been 
observed 24 and 48 hours following the injection of L-arginine (191). Some studies 
suggest that the combination of NO with superoxide (O2-) produced in the arginase 
pathway leads to the production of reactive nitrogen species, which would contribute 
to the oxidative stress causing pancreatitis in the L-arginine model (73, 188, 189, 
192). In addition, neuronal and endothelial cells present in close proximity to 
pancreatic acinar cells may also contribute to the increase in reactive oxygen and 
nitrogen species!(193).  Studies using NOS inhibitors, such as L-NAME, or 
antioxidants reported both protective effects and no improvement in severity of 
pancreatitis. (187, 191, 194-196). Furthermore, intraperitoneal administration of NO 
donor sodium nitroprusside or L-citrulline, the NO liberating metabolite, failed to 
induce pancreatitis (187). Thus, the role of iNOS in the induction of pancreatitis in 
the L-arginine model is still remains. Some studies even suggest a protective role for 
NO during acute pancreatitis by increasing the pancreatic microvascular blood flow, 
inhibiting leukocyte activation, and protecting against trypsinogen activation and 
acinar cell necrosis (189, 195, 197). 
It is not well understood why only the pancreas and not other abdominal 
organs is affected in the L-arginine model (180-182).  It was suggested that this 
could be due to the high turnover of proteins in pancreatic acinar cells, which would 
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cause them to import large quantity of L-arginine more rapidly than in other organs. 
In addition, the presence of large amount of digestive enzymes in pancreatic acinar 
cells could be an explanation for the specific effect of L-arginine on the pancreas.  
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CHAPTER 2: HYPOTHESES AND OBJECTIVES 
2.1 Hypotheses: 
1) Acute necrotizing pancreatitis (ANP) in dogs is accompanied by acute lung 
injury (ALI) and is associated with the induction of pulmonary intravascular 
macrophages (PIMs). 
2) PIMs are recruited in the L-arginine ANP mouse model. 
 
2.2 Objectives: 
A. To characterize lung inflammation in clinical cases of ANP in dogs using 
histological evaluation and immunohistochemical staining with special focus 
on the recruitment of mononuclear phagocytes. 
B. To induce ANP in mice using the L-arginine model and to assess lung 
inflammation including the induction of PIMs. 
 
2.3 Rationale:  
Dogs suffering from ANP often develop a systemic inflammatory response 
syndrome leading to multiple organ dysfunction syndrome with high mortality rates. 
Among all systemic complications that are associated with severe acute pancreatitis 
(AP) in humans, ALI or its more severe form acute respiratory distress syndrome 
(ARDS) are responsible for up to 60% of the mortality (11). The incidence of 
pulmonary complications in dogs with AP is not well established. However, signs of 
respiratory distress in those dogs are reported as a cause of death or euthanasia 
clinically and in the literature (2). The pathophysiology leading to ALI is not well 
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understood and the majority of our knowledge comes from studies using rodent 
models of AP. Very little is known about the specific mechanisms such as the 
recruitment and functions of pulmonary intravascular macrophages (PIMs) in the 
lungs of dogs with AP. Because there has not been any detailed study of the lung 
histology in dogs that have died due to AP (or ANP), I propose to fill this gap with a 
special focus on the characterization of recruitment of PIMs and expression of 
selected inflammatory molecules. Following this, I will investigate lung inflammation 
including recruitment of PIMs in a mouse model of L-arginine-induced ANP. While 
data from the lungs of spontaneous cases of ANP in dogs provides valuable insights 
into the potential contributions of lung inflammation to mortality, the mouse model 
will provide a platform to dissect specific mechanisms contributing to the 
development of lung injury observed in AP. 
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CHAPTER 3: LUNG INFLAMAMTION IN CLINICAL CASES OF ANP IN DOGS 
 
3.1 Introduction 
 
AP in dogs is one of the most common gastrointestinal causes of emergency 
admissions in small animal veterinary clinics (2, 3). While AP can occur in a mild 
form with low morbidity, the severe form of AP, acute necrotizing pancreatitis (ANP), 
is associated with systemic inflammatory response syndrome and multiple organ 
dysfunction syndrome with high mortality rates. When suffering from this disease, 
the risk of mortality can increase up to 27-58% (2-4) and this significant mortality 
rate is mainly associated with the various systemic complications associated with 
ANP. In human patients suffering from severe AP, acute lung injury (ALI) or its more 
severe form acute respiratory distress syndrome (ARDS) are responsible for up to 
60% of the mortality occurring in the first week of the disease (10, 11). Furthermore, 
the incidence of ALI in people with AP varies form 18%-46% (12-15) depending on 
the severity of AP. There are two retrospective studies that reviewed the medical 
records of dogs with AP, which reported clinical evidence of dyspnea or tachypnea 
in 4/61 dogs (7%)(2) in the first study and 18/80 dogs (23%) in the second (5). 
ALI or ARDS are common devastating conditions associated with high 
morbidity and mortality in humans and animals. The pathophysiology of ALI is 
complex and involves a vascular and cellular response. During indirect ALI, the 
vascular endothelial cells constitute the first cells to be exposed to inflammatory 
mediators. Activation of those cells can lead to structural changes of the lung 
microvasculature leading to increased vascular permeability, expression of adhesion 
molecules on endothelial cells and production of chemokines resulting in the 
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recruitment and migration of leukocytes into the lungs. Neutrophils are typically the 
first inflammatory cells to be recruited into the lungs during ALI and play an 
important role in clearing pathogens (83). However, excessive recruitment of 
neutrophils through various adhesion molecules including selectins and integrins 
can cause further lung injury through the release of their granules content, such as 
ROS and proteases (83).  
The cellular response during ALI is strongly modulated by the pulmonary 
resident macrophages including alveolar macrophages, interstitial macrophages and, 
in some species, pulmonary intravascular macrophages (PIMs). PIMs are highly 
phagocytic large cells (20-80µm diameter) with characteristics of mature 
macrophages and are believed to have pro-inflammatory functions. Some species in 
the orders Artiodactyla (cattle, water buffalos, sheep, goats and pigs) (97-104), 
Perissodactyla (horses) (105-107), Odontoceti cetacean (toothed whales) (108) and 
some strains of domestic cat (109) have been shown to have constitutive PIMs. 
Furthermore, PIMs can be induced with physiological stress such as endotoxemia 
and liver dysfunction (111, 112) in species that do not normally have them including 
Rodentia (rats, mice, guinea pigs, hamsters) (110) (101) and Lagomorpha (rabbits) 
(111, 112). To my knowledge there are no studies that have assessed the induction 
of PIMs in dogs suffering from ANP-associated lung injury. Although the 
mechanisms are not well known, PIMs stimulation or induction would enhance the 
host susceptibility to lung injury during subsequent microbial challenges(111). 
ALI associated with AP would be multifactorial resulting from the complex 
combination of the release into the blood circulation of pancreatic-specific proteins 
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(147, 156, 157, 164, 171, 172), activation of Kupffer cells (143-146) and peritoneal 
macrophages (148, 151, 152), gut barrier dysfunction(198, 199), and the activation 
of alveolar macrophages (AM) in the lungs. Most studies assessing ALI in 
experimental AP studies using rodent models have focussed on the role of AM, 
which have been shown to be activated during AP by various mechanisms leading 
to the acquirement of a pro-inflammatory phenotype. (164-169). Following their 
activation, alveolar macrophages cause lung injury producing pro-inflammatory 
mediators such as of TNFα, IL-1β, and MIP-2 resulting in the recruitment of 
neutrophils into the lungs and in lung injury (147, 164, 170-172).  In addition, 
alveolar macrophages have been shown to express high levels of inducible nitric 
oxide synthase (iNOS) in various experimental AP studies resulting in increased 
levels of nitric oxide (NO) in the lungs. (164, 171) (173). The role of NO during ALI 
associated with AP is controversial because in some studies the increase in NO has 
been associated with more lung injury (164, 173) (140) whereas in others NO was 
protective and reduced the severity of ALI (174). Although significant progress has 
been made to characterize the role of alveolar macrophages during ALI in rodent 
models of AP, no study has assessed the recruitment and role of PIMs during this 
disease. 
The majority of our knowledge on ALI associated with AP comes from studies 
using rodent models of AP and very little is known about the specific mechanisms 
occurring in dogs with ANP. Therefore, in this study, the lungs of 21 dogs that died 
or were euthanized because of ANP were evaluated to characterize the presence of 
ALI with a particular interest for the presence of PIMs. In addition, 
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immunohistochemistry for TLR4 and IL6 was performed to further characterize pro-
inflammatory mechanisms in the lungs of ANP dogs. iNOS expression was also 
assessed by immunohistochemistry since NO seams to be involved in ALI 
associated with AP in rodent models. Lastly, von Willebrand Factor (vWF) was 
previously shown in our laboratory to be increased in inflamed lungs, therefore its 
expression in lungs of ANP dogs was also described with immunohistochemistry. 
 
3.2 Materials and Methods 
 
3.2.1 Selection of canine ANP cases  
Cases of dogs that died or were euthanized from ANP were selected by 
searching the medical records of the Veterinary Medical Center (VMC) of the 
Western College of Veterinary Medicine (WCVM) between the years of 2000 to 
2013 and using the keywords ‘necrotizing pancreatitis’ and ‘pancreas necrosis’. A 
search was also made in the Prairie Diagnostic Services Inc. (PDS) electronic 
system to identify external cases of ANP dogs that were sent to PDS for the post-
mortem evaluation and that may not have been included in the VMC database. Then, 
the necropsy reports from the identified cases were reviewed to confirm the post-
mortem diagnosis of ANP and to select cases where both lung and pancreas were 
collected during necropsy for paraffin embedding. Cases with a mention of 
significant post-mortem/autolysis on the necropsy reports or cases where the 
carcass had been frozen were excluded because of the importance of the tissue 
quality for immunohistochemistry. Finally, two American College of Veterinary 
Pathologists (ACVP) board-certified veterinary pathologists reviewed the 
haematoxylin and eosin staining (H&E staining) slides of the pancreas from all 
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selected cases to confirm the diagnosis of ANP (described bellow). After this 
selection process, 21 ANP dog cases remained, including 4 external cases and 17 
VMC cases.  
3.2.2 Control dogs 
Six dogs euthanized at the Saskatoon Society for the Prevention of Cruelty to 
Animals (SPCA) for behaviour reasons (aggressive behaviour) were used as control 
dogs.  Each dog was visually evaluated before being euthanized for general health 
status (hair quality, weight, energy level, alertness) and for signs of respiratory 
diseases such as coughing, nasal discharge, abnormal respiratory patterns and 
lethargy. All SPCA dogs appeared healthy. The signalment information was also 
recorded for every dog. Further clinical evaluation could not be performed under 
agreements made with the SPCA. The SPCA staff performed the euthanasia of the 
animals.  
 
3.2.3 Review of ANP dogs medical records 
Medical records for the 17 cases of ANP from the VMC were reviewed and 
data regarding the presence of respiratory clinical signs, leukograms, presence of 
DIC, and concomitant conditions were recorded. If multiple blood analyses were 
available, leukograms performed within 48 hours prior to death were used in order to 
be more consistent between cases. Blood work done at the time of presentation was 
not used as 3 cases were hospitalized 5-10 days before death for other reasons 
than ANP and use of those blood results would not have been representative of 
changes caused by ANP. Inflammatory leukograms when present were divided into 
! 35!
two categories based on severity: 1) inflammatory leukogram defined as white blood 
cell (WBC) count ≥ 20.0 X 109 cells/L or ≤ 4.0 X 109 cells/L, with ≤ 10% band 
neutrophils and 2) severe inflammatory leukogram defined as WBC count ≥ 20.0 X 
109 cells/L or ≤ 4.0 X 109 cells/L, neutrophil count ≤ 1.0 X 109 cells/L, or ≥ 10% band 
neutrophils (2). The presence or absence of concomitant peritonitis and endocrine 
diseases was based on cytology of abdominal fluid and blood analyses, respectively.  
The presence of peritonitis was also confirmed with the post-mortem evaluation. 
Concomitant hepatic, renal and gastrointestinal diseases were recorded based on 
the post-mortem findings. For the 4 external cases, the histories provided with the 
post-mortem evaluation requests were considered detailed enough to be included 
into the case reviews. However, leukograms were not available for the 4 external 
cases and were not performed on 3 VMC cases. 
 
3.2.4 Lung and pancreas tissue samples 
Formalin-fixed and paraffin-embedded lung and pancreas from all 21 ANP 
cases were provided by the PDS of the WCVM. One paraffin block per animal per 
organ was used. Each lobe of the lungs and both right and left lobes of the pancreas 
from the control dogs was sampled (1cm2) for fixation in 4% paraformaldehyde 
overnight at 4oC (between 16-20h) followed by embedding in paraffin (see Appendix 
I Table A for complete protocol). In addition, portions of the lung and pancreas 
samples were snap-frozen in liquid nitrogen.  
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3.2.5 Canine pancreas histology grading 
Two board-certified pathologists from the Department of Veterinary Pathology 
at the WCVM, who were blinded to the identity of the samples, independently 
graded the pancreatic histology to confirm the diagnosis of ANP. They also 
evaluated tissues from control dogs to ensure that they had normal pancreas. While 
H&E stained slides from the ANP cases were provided by PDS, I performed the 
staining on the tissues from the control dogs.  
 The pancreatic tissues from the ANP and control dogs were graded for the 
presence of 1) pancreatic necrosis 2) infiltration of inflammatory cells in the 
pancreas and 3) pancreatic edema. The evaluators also recorded the identity of the 
inflammatory cells infiltrating the pancreas. The scoring system is described in Table 
B. The summation of the scores obtained from each of the three criteria evaluated 
gave the histology score. An average was calculated from the histology scores 
obtained for each pathologist in order to generate a final pancreas histology score 
for each dog. 
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Table B: Grading system used to evaluate canine pancreas histology 
Grading criteria Score Description 
Pancreas 
necrosis 
0 Absence of pancreas necrosis 
1 Necrosis in <10% of the pancreas parenchyma 
2 Necrosis in 10-25% of the pancreas parenchyma  
3 Necrosis in 25-50 % of the pancreas parenchyma  
4 Diffuse pancreas necrosis; >50% of the pancreas parenchyma 
Pancreas edema 
0 Absence of pancreas edema 
1 Focally increased space between lobules 
2 Diffusely increased space between lobules 
3 Pancreatic acini disrupted and separated 
Infiltration of 
inflammatory 
cells in the 
pancreas 
0 Absence of inflammatory cell infiltration in the pancreas 
1 Rare inflammatory cell or around ductal margins 
2 
Inflammatory cell infiltration in the pancreas parenchyma (<50% of 
the lobules) 
3 
Inflammatory cell infiltration in the pancreas parenchyma (>50% of 
the lobules) 
Type of 
inflammation     Neutrophilic, monocytic, lymphocytic, mixed 
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3.2.6 Canine lung histology grading  
The lung histology from each dog was evaluated by the same two board-
certified pathologists independently and they were blinded to the identity of the 
cases. The lungs of ANP and control dogs were scored for signs of inflammation 
based on 1) alveolar septa thickening and 2) the presence of lung edema. The type 
of inflammatory cells infiltrating the lungs was also recorded. The scoring system is 
described in Table C. The summation of the scores obtained from both criteria 
evaluated gave the histology score. An average was made with the histology scores 
obtained for each pathologist in order to generate a final lung histology score for 
each dog. 
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Table C: Grading system used to evaluate canine lung histology 
Grading criteria Score Description 
Lung edema 
0 Absence of lung edema 
1 Mild lung edema 
2 Moderate lung edema 
3 Severe lung edema 
Alveolar septa thickening 
0 Absence of alveolar septa thickening 
1 Mild alveolar septa thickening 
2 Moderate alveolar septa thickening 
3 Severe alveolar septa thickening 
Type of inflammation Neutrophilic, monocytic, mixed 
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3.2.7 Immunohistochemistry on canine lung tissue 
To perform immunohistochemistry, paraffin sections of lungs from ANP and 
control dogs were de-paraffinized in xylene for 30 minutes and rehydrated in 
descending concentrations of ethanol (100%-95%-70%-50%) for 10 minutes each. 
The slides were then incubated with 0.5% H2O2 in methanol for 20 minutes to 
quench the endogenous peroxidase activity. Antigen retrieval was performed using 
pepsin (2 mg/ml in 0.01N HCl) for one hour (for macrophage, IL6, iNOS and vWF 
staining) or by heat-induced epitope retrieval (HIER) using boiling citrate buffer pH 
6.0 in which slides were submerged in a staining rack for 20 minutes (for TLR4 
staining). Both pepsin and HIER methods are used to break the tissue protein cross-
linking caused by aldehyde-containing fixative such as formalin. This cross-linking 
can mask protein epitopes and prevent the binding of the primary antibody to its 
antigen resulting in a lack of staining. Blocking was done using bovine serum 
albumin (BSA) (1% in PBS) for 30 minutes at room temperature after which slides 
were incubated with the primary antibodies overnight (16 hours) at 4°C with 
antibodies against macrophages, IL6, TLR4, iNOS, and vWF (dilutions and antibody 
sources in Table D). Slides were washed 3x 5 minutes in PBS 1x to remove excess 
antibodies. Then, tissue sections were incubated for 30 minutes at room 
temperature with the appropriate horseradish peroxidase (HRP) conjugated 
secondary antibody. Color development was performed using a commercial kit 
(VECTOR VIP Peroxidase Substrate Kit; Vector laboratories, Burlingame, CA) 
followed by counter staining using nuclear counter stain methyl green (Vector 
laboratories). Slides were dehydrated using ascending concentration of ethanol 
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(50%-70%-95%-100%) 1 minute each then put in xylene for 5 minutes followed by 
mounting of coverslips.  
The negative control consisted of omitting the primary antibody for every 
different secondary antibody used. In addition, isotype-matched controls were 
performed by substituting each primary antibody with the appropriate 
immunoglobulin isotype. vWF staining was used as a marker of inflammation but 
also as a control for the immunohistohemical protocol as it is normally present in 
Weibel Palade bodies (WPb) of endothelial cells. 
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Table D: List of antibodies used on dog lung tissues with respective dilutions and 
sources 
 
Primary antibodies 
Antibody 
Dilution in 
BSA 1% 
Source 
Monoclonal mouse anti-human macrophage 
clone MAC387 (MCA874G) 
1:75 AbD Serotec 
Polyclonal goat anti-mouse IL6 (sc-1265) 1:50 
Santa Cruz 
Biotechnology 
Polyclonal goat anti-mouse TLR4 (sc-12511) 1:50 
Santa Cruz 
Biotechnology 
Polyclonal rabbit anti-human iNOS (sc-651) 1:25 
Santa Cruz 
Biotechnology 
Polyclonal rabbit anti-human vWF (P0448) 1:500 DAKO 
Secondary antibodies 
Horseradish peroxidase (HRP) conjugated 
secondary antibodies 
1:100 
(Except for vWF 
staining: 1:300) 
All from DAKO 
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3.2.8 Quantification of MAC387 immunohistochemistry 
Lung sections from ANP and control dogs were stained using the monoclonal 
mouse anti-human macrophage antibody (clone MAC387) as described above. This 
antibody binds to calprotectin (200-202), which is mainly present in macrophages, 
but can also be present in monocytes and neutrophils. For every ANP and control 
dog, positively stained macrophages/monocytes and positively stained neutrophils 
were counted independently in 20 fields of view at 600X following a consistent 
counting pattern for each slide. A field of view was considered appropriate for 
counting if about more than 50% of the view was covered by lung parenchyma. 
Fields of view where more than 50% of the area was covered with airways 
(bronchiole) or blood vessels were ignored moving to the next field of view. 
Neutrophils and macrophages/monocytes could be differentiated from each other by 
evaluating the cell morphology. Neutrophils showed intra-nuclear staining, therefore, 
making the multi-lobulated nucleus of neutrophils easy to recognize. Monocyte and 
macrophage reaction to the antibody was characterized by staining of the nucleus 
and the cytoplasm. Representative images of MAC387 staining of the different cell 
types are shown in Figure 3.1. The counts from all 20 fields of view were combined 
resulting in a total neutrophil count and a total macrophages/monocytes count for 
every dog. Those two total counts were also combined resulting in a total 
inflammatory cell count for every dog.   
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Figure 3.1. Example of MAC387 staining. MAC387 staining of a neutrophil (left) 
and mononuclear phagocytes (right) in a dog lung section.  
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3.2.9 Interpretation of immunohistochemical markers of inflammation  
Immunohistochemistry of vWF, TLR4, IL6, and iNOS was qualitatively 
evaluated. For vWF staining, the presence or absence of positive staining was 
recorded for the following cells: 1) medium-large blood vessel endothelial cells, 2) 
alveolar septal capillary endothelial cells, 3) alveolar macrophages, and 4) 
mononuclear phagocytes in alveolar septal capillaries. For the staining of TLR4, IL6, 
and iNOS, the presence or absence of positive staining was recorded for the 
following cells: 1) airway epithelial cells (apical, cytoplasmic or basal staining) 2) 
medium-large blood vessel endothelial cells, 3) alveolar macrophages 4) 
mononuclear phagocytes in alveolar septal capillaries and 5) alveolar septa. This 
evaluation was performed for all dogs in the study. 
 
3.2.10 Statistical analysis  
Statistical analysis was performed using statistical software (GraphPad Prism, 
Version 5.04 for Windows, GraphPad Software, San Diego California USA). Data 
from the histological grading and MAC387 counting are expressed as median with 
the range. Comparison between control and ANP dog medians were done with the 
non-parametric test: Mann-Whitney U. P < 0.05 is considered significant. 
The strength of the association between lung histology scores versus 
pancreas histology scores and the association between MAC387 counts and 
pancreas histology scores were assessed by Spearman Rank correlation coefficient. 
Correlation coefficients were interpreted as follows: r = 0, no correlation; 0 < r < 0.1, 
trivial correlation; 0.1 ≤ r < 0.3, slight correlation; 0.3 ≤ r < 0.5, moderate correlation; 
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0.5 ≤ r < 0.7, substantial or high correlation; and r ≥ 0.7 very high correlation (226). 
Comparison of MAC387 count medians between dog cases with or without 
peritonitis was performed by Mann-Whitney U. P < 0.05 is considered significant for 
Mann-Whitney U test. 
 
3.3 Results 
 3.3.1 Clinical description of control and ANP dogs  
The signalment information for control and ANP dogs is described in Table E. 
Various breeds were represented in the ANP group with no sex predisposition. ANP 
dogs were generally older dogs with a median age of 8 years. All ANP dogs (except 
for 3 dogs) were presented to the emergency and died or were euthanized within 48 
hours. The other 3 dogs were admitted 5-10 days prior to death. Clinical evidence of 
pulmonary complications was recorded in 4/21(19%) dogs and included pleural 
effusion in 3 dogs (one dog with dyspnea) and increased lung sounds only in the 
fourth dog. All ANP dogs that had a complete blood count (CBC) done (n=14) within 
the last 48 hours prior to death showed inflammatory leukograms, which was divided 
into two categories based on severity described earlier resulting in 3 dogs with 
inflammatory leukograms and 11 dogs with severe inflammatory leukograms. 
Concomitant conditions/complications included liver diseases, kidney diseases, 
peritonitis, DIC and more. The incidence of different concomitant 
conditions/complications is listed in Table F. 
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 3.3.2 Pancreas histology grading  
Representative histology of pancreas from control and ANP dogs is shown in 
Figure 3.2.  The histological evaluation of pancreas of control dogs resulted in 
scores of ’’0’’ for every scoring category leading to a total pancreas histology score 
of ‘’0’’ for every control dog (n=6), as shown in Figure 3.3. This confirmed that 
control dogs had normal histology of the pancreas and that they were suitable 
control animals for this study.  
The results from the grading of pancreatic histology in ANP dogs are shown 
in Figure 3.3 and are as follows: necrosis of pancreas (median, 2; range, 1-4), 
infiltration of inflammatory cells in the pancreas (median, 1.5; range, 0-3) and 
pancreatic edema (median, 2; range 0.5-3). The median value for the total pancreas 
histology scores for ANP dogs was 4.5 (range 2.5 – 9.5) indicating variation in the 
severity of pancreatitis among cases. The presence of pancreatic necrosis 
confirmed the diagnosis of ANP. The extent of pancreatic necrosis varied from 
<10% to > 50 % of the parenchyma. In addition, infiltration of inflammatory cells in 
the pancreas varied from none (4 ANP dogs) to massive infiltration in > 50 % 
pancreas parenchyma. The type of pancreatic inflammation when present was 
mainly neutrophilic (n=12), but also monocytic (n=3), mixed (n=1) and lymphocytic 
(n=1). Pancreatic edema varied from a focally increased space between lobules to 
disrupted and separated pancreatic acini. There was a moderate correlation 
between the severity of pancreas necrosis and the infiltration of inflammatory cells 
into the pancreas (Spearman Rank correlation coefficient r = 0.37).  
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3.3.3 Lung histology grading  
Representative lung histology from control and ANP dogs is shown in Figure 
3.4.  The results from the histologic grading of lung tissue sections for signs of 
inflammation in ANP and control dogs are as follows: alveolar septal thickening 
(control median: 0.25; range 0-1.5, ANP median: 1; range 0-2.5) and lung edema 
(control median: 0.25; range 0-0.5, ANP median: 0.5; range 0-2). This resulted in the 
following total lung histology scores: control median: 0.5; range 0-2 and ANP 
median: 1.5; range 0-3, as shown in Figure 3.5. Although these results were not 
statistically significant, lung sections from some of the dogs suffering form ANP 
showed signs of lung inflammation such as moderate edema and accumulation of 
inflammatory cells, mostly mononuclear phagocytes, in the alveolar septa, and an 
increase in alveolar macrophages. The pathologists did not agree on the identity of 
infiltrating cells in lungs of two of the ANP dogs. One of the control dogs showed 
infiltration of mononuclear phagocytes corresponding to an alveolar septal 
thickening score of 1.5.  
As for the lung edema criterion, there was an initial disagreement between 
pathologists regarding the true significance of the protein-rich fluid present in the 
alveolar spaces. Indeed, for some cases, one pathologist considered the protein-rich 
fluid as a real pathological edema lesion (leading to a high score for edema) and the 
other pathologist as an artifact (leading to a score of ‘’0’’). Therefore, a third 
independent pathologist evaluated the slides with lack of consensus and the scores 
were corrected based on the interpretation of the majority (real edema or artifact).   
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3.3.4 Macrophage immunohistochemical staining 
 Representative images of the immunohistochemical controls are shown in 
Figure 3.6. Negative control omitting the primary antibody or isotype-matched 
controls resulted in absence of staining in the tissues. Positive control using vWF 
antibody stained specifically blood vessels validating the IHC protocol. Lung 
sections from all ANP and control dogs were staining with monoclonal mouse anti-
human macrophage antibody (clone MAC387), which recognizes the antigen 
calprotectin (200-202). Calprotectin is mainly expressed in macrophages but can 
also be present in monocytes and granulocytes. For that reason, mononuclear 
phagocytes (including macrophages and monocytes) and neutrophils were counted 
separately as described earlier. It is important to note that the MAC387 antibody did 
not stain alveolar macrophages; therefore, those cells were not included in the 
counts. Representative images of the MAC387 staining are shown in Figure 3.7. 
The results for neutrophil counts in the lungs are as follows: for control dogs 
(median, 70; range 31-129) and for ANP dogs (median, 25.5; range 5-121, with one 
outlier at 579 cells). The decrease in the number of neutrophils in ANP dog’s lung 
was statistically significant compared to the control dogs (p < 0.05) (Figure 3.8 A). 
Neutrophils were present in alveolar septal capillaries only and not in the alveoli in 
both control and ANP dogs. The counts for monocytes/macrophages in the lungs 
are as follows: for control dogs (median:1.5; range 0-16) and for ANP dogs (median, 
138; range 31-935). The increase in the number of monocytes/macrophages in 
lungs from ANP dogs was statistically significant compared to the control dogs (p < 
0.001; Figure 3.8B). The total inflammatory cells (Figure 3.8C) in the lungs of ANP 
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dogs (median, 170; range 44-1100) were significantly (p < 0.05) more than in the 
control dogs (median, 71; range 33-145).  
 
3.3.5 vWF immunohistochemical staining 
Staining with a vWF antibody was used as a positive control to standardize 
the IHC protocol as mentioned previously. However, it was previously observed in 
our laboratory that the staining for vWF is increased in inflamed lungs (203). 
Therefore, the lungs from all the dogs in the study were stained with this antibody as 
a marker of inflammation. 
As expected, each dog (control and ANP) showed staining of endothelial cells 
of larger blood vessels (Figure 3.9 A-B). However, in ANP dogs, there was also 
robust staining of endothelial cells forming alveolar septal capillaries, which was not 
observed in control dogs (Figure 3.9 C-D). Also, ANP dogs showed intra-
cytoplasmic staining of vWF in mononuclear phagocytes infiltrating the alveolar 
septal capillaries (see Figure 3.9 D-E) and, in some cases, in the cytoplasm of 
alveolar macrophages (see Figure 3.9 F). These two findings were not observed in 
control dogs. At a higher magnification, it was possible to note granular staining in 
the alveolar septal capillaries, which was only observed in the lungs from ANP dogs 
(see Figure 3.9 D). A summary of the vWF staining with the frequency of each 
observation in the control and ANP group is described in Table G. 
 
 
 
 
! 51!
3.3.6 TLR4 immunohistochemical staining 
Every control and 18 out of 21 ANP dogs showed TLR4 staining in the 
vascular endothelium of medium blood vessels (Figure 3.10 A). Only faint 
occasional staining was seen in mononuclear phagocytes present in alveolar septa 
of lungs from control dogs (Figure 3.10 A). Control dogs lacked staining for TLR4 in 
alveolar macrophages whereas half of ANP dogs showed strong TLR4 staining in 
the cytoplasm and nucleus of alveolar macrophages (Figure 3.10 B). In addition, 
18/21 ANP dogs showed staining for TLR4 in inflammatory cells present in alveolar 
septal capillaries (mainly mononuclear phagocytes) and 4 dogs showed staining of 
the alveolar septal capillaries (Figure 3.10 B). Some staining for TLR4 was present 
in the airway epithelium of every control dog. The staining was granular and 
irregular and mainly cytoplasmic or present between epithelial cells (Figure 3.10 C). 
Interestingly, the staining pattern for TLR4 in airway epithelial cells in ANP dogs 
varied from cytoplasmic staining (4/21 ANP dogs), to apical staining (3/21 ANP 
dogs), basal staining (9/21 dogs), granular and irregular staining of the cytoplasm as 
in control dogs (8/21 dogs), and lack of staining on some of the epithelium (8/21 
dogs) (Figure 3.10 D). A summary of the TLR4 staining with the frequency of each 
observation in the control and ANP group is described in Table G. 
 
3.3.7 IL6 immunohistochemical staining  
The IL6 staining was mainly observed in alveolar macrophages and 
mononuclear phagocytes present in alveolar septa. While nearly half of the control 
dogs rarely showed an alveolar macrophage positive for IL6 (Figure 3.11 A), 66% of 
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the ANP dogs showed robust staining for IL6 in alveolar macrophages and in some 
mononuclear phagocytes present in alveolar septa (Figure 3.11 B). There was no 
staining of other structures of the lungs in control and ANP dogs. A summary of the 
IL6 staining with the frequency of each observation in the control and ANP group is 
described in Table G. 
 
3.3.8  iNOS Immunohistochemical staining  
The main finding regarding IHC staining for iNOS was the localization of 
iNOS in alveolar macrophages of 13/21 dogs with ANP (Figure 3.12 B). iNOS 
staining was absent in the alveolar macrophages from control dogs (Figure 3.12 A).  
There was no staining of other structures of the lungs in control and ANP dogs. A 
summary of the iNOS staining with the frequency of each observation in the control 
and ANP group is described in Table G. 
 
3.3.9 Statistical associations between lung inflammation and ANP 
severity  
To evaluate if the severity of lung inflammation was correlated with the 
severity of ANP, the associations between the lung histology scores or infiltration of 
mononuclear phagocytes in the lungs (MAC387 counts) and the pancreas scores 
obtained in the different pancreatitis histology criteria were done with Spearman 
Rank correlation. Lung histology scores and the different pancreatitis criteria scores 
did not show correlation (Table H). However, using the counts for mononuclear 
phagocytes in the lungs (MAC387) instead of lung histology scores resulted in 
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higher correlation coefficients (Table H). The best correlation obtained was between 
the infiltration of mononuclear phagocytes in the lungs and the scores for infiltration 
of inflammatory cells in the pancreas with a Spearman Rank correlation coefficient 
of r=0.46 (or r=0.49 without the outlier value); p < 0.05, considered as moderate 
correlation. Correlation graphs are illustrated in Figure 3.13. As peritonitis can occur 
secondary to severe AP, the infiltration of mononuclear phagocytes in the lungs 
(MAC387 counts) was also compared between dogs with (median: 138 counts, 
range: 106-619) or without (median: 139 counts, range: 31-950) peritonitis but there 
was no statistical difference between groups (p=0.4636).   
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Table E: Control and ANP dogs’ signalment 
 Control dogs (SPCA) ANP dogs 
Breed 
Medium-size mixed breeds: n=3 
Border Collie: n=1 
Dachshund: n=1 
Pitbull:  n=1 
Terriers: n= 5 
American cocker spaniel: n=3 
Border Collie: n=3 
Shetland sheepdog: n=3 
Labrador: n=2 
Toy poodle: n= 2 
Pug: n= 1 
Samoyed: n=1 
Miniature Schnauzer: n=1 
Age (y) Median 4.5 (range 1-6) Median 8 (range 4-12) 
Sex 
(reproductive 
status) 
Female: n=3 (unknown) 
Male: n= 3 (3C) 
Female: n=9 (7S) 
Male: n=12 (10C) 
Y: Years  C: Castrated  S: Spayed 
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Table F: Incidence of concomitant conditions/clinical findings in 21 ANP dogs 
System No of dogs (%) 
 
From clinical assessments 
 
Respiratory 
• Pleural effusion (one dog with dyspnea)  
• Increased lung sounds only  
 
Hematopoietic (n=14 for leukograms) 
• Inflammatory leukogram* 
• Severe inflammatory leukogram**  
 
Peritoneum  
• Peritonitis (suppurative or necrotizing) 
 
Endocrine 
• Pre-existing diabetes mellitus 
• Diabetic ketoacidosis 
 
Disseminated intravascular coagulation 
 
From post-mortem diagnosis 
 
Hepatic  
• Chronic hepatitis 
• Lipidosis 
• Hepatic necrosis 
 
Renal  
• Glomerulonephritis 
• Tubular necrosis 
• Glomerulosclerosis 
• Extensive lipidosis 
 
Gastrointestinal  
• Duodenum necrosis 
• Enteritis (all type) 
 
 
 
 
3 (14%) 
1 (5%) 
 
 
3 (21%) 
11 (79%) 
 
 
8 (38%) 
 
 
3 (14%) 
2 (9%) 
 
4 (19%) 
 
 
 
 
4 (19%) 
5 (24%) 
5 (24%) 
 
 
8 (38%) 
2 (9%) 
3 (14%) 
1 (5%) 
 
 
1 (5%) 
5 (24%) 
 
* Inflammatory leukogram: WBC count ≥ 20.0 X 109 cells/L or ≤ 4.0 X 109 cells/L, with ≤ 10% 
band neutrophils. (2) 
** Severe inflammatory leukogram: WBC count ≥ 20.0 X 109 cells/L or ≤ 4.0 X 109 cells/L, 
neutrophil count ≤ 1.0 X 109 cells/L, or ≥ 10% band neutrophils (2) 
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Figure 3.2. H&E staining of dog pancreas. (A): Pancreas histology of a control 
dog with normal parenchyma and clear spaces between pancreatic lobules. (B): 
Dog with ANP showed infiltration of inflammatory cells between pancreatic 
lobules, (C): acinar cell (AC) disruption and separation and (D): severe acinar cell 
necrosis of multiple pancreatic lobules.  
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Figure 3.3. Pancreas histology grading scores of ANP (n=21) and control (n=6) 
dogs. (A): Scores for pancreas necrosis. (B): Scores for infiltration of inflammatory 
cells in the pancreas. (C): Scores for pancreas edema. (D): Histology scores 
(represent the sum of the 3 different scoring categories). Median values represented 
by horizontal line in graphs. Significant differences from control dogs at p < 0.05 
denoted as asterisks (*). 
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Figure 3.4. H&E staining of dog lungs. (A+C): Lungs from control dogs show 
normal alveolar septa with only few numbers of alveolar macrophages (arrows). 
(B): ANP dogs showed infiltration of inflammatory cells in alveolar septa. (D): 
Inflammatory cells infiltrating ANP dog’s lung alveolar septa were mainly 
mononuclear phagocytes (dotted line arrows). In addition, increased numbers of 
alveolar macrophages were noted in ANP dogs (arrows). AW: Airway, A.S.: 
Alveolar space. 
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Figure 3.5. Lung histology grading scores for ANP (n=21) and control 
(n=6) dogs. (A): Lung edema scores. (B): Alveolar septal thickness scores. (C): 
Lung histology scores (represent the sum of the 2 different scoring categories). 
Median values represented by horizontal line in graphs. The scores for ANP 
dogs were not statistically different from control dogs. 
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Figure 3.6. Immunohistochemistry controls. (A): Representative picture of the 
negative control omitting the primary antibody. (B): Isotype-matched control 
showing absence of staining. (C): Positive control using an anti-vWF antibody 
showing specific staining of the vascular endothelium in large blood vessel (thick 
arrow) and in microvessels (thin arrows). Notice that airway epithelial cells are not 
stained (arrowheads).  
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Figure 3.7 MAC387 immunohistochemical staining in dog’s lungs. (A+C): 
Rare MAC387-positive cells (arrow heads) present in control dog lungs, which 
are mainly neutrophils. (B+D): Massive infiltration of MAC387-positive cells in 
alveolar septa of ANP dog lungs including neutrophils and mononuclear 
phagocytes.  
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Figure 3.8 MAC387-positive cell counts in dog lungs (A): Neutrophils counts for 
controls and ANP dogs lungs. Except for one outlier case, ANP dogs had less 
neutrophils in their lungs compared to controls. (B): There was a significant increase of 
macrophages/monocytes in lungs of ANP dogs compared to control dogs. (C): Taken 
together, ANP dogs have more inflammatory cells infiltrating their lungs compared to 
the controls. Median values represented by horizontal line in graphs. One asterisk (*) 
denotes significant differences from control dogs at p < 0.05. Two asterisks (**) 
denotes a significant difference from control dogs at p < 0.001. 
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Figure 3.9. Immunohistochemical staining for vWF in dog lungs. (A+B): Lungs 
of control dogs showed staining for vWF only in endothelial cells of medium-large 
blood vessels (arrows). There was no staining for vWF in alveolar septa, as shown 
in (B). (C): As for the control dogs, ANP dogs showed staining of medium-large 
blood vessels (arrows) but also of alveolar septa (dotted line arrow). (D): At higher 
magnification, staining of mononuclear phagocytes infiltrating alveolar septa is seen 
(arrowheads). There is also presence of granular staining in alveolar septal 
capillaries (arrow with circle) of unknown nature. (E): Positively stained 
mononuclear phagocytes (arrowheads) with strong staining of the cytoplasm. (F): 
Positively stained alveolar macrophages (thin arrows) with strong staining of the 
cytoplasm. AW: Airway, A.S.: Alveolar space, B.V.: Blood vessel.  
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Figure 3.10. Immunohistochemical staining for TLR4 in dog lungs. (A): 
Control dogs showed TLR4 staining of the vascular endothelium (arrows) and 
occasional pale staining of inflammatory cells in alveolar septal capillaries (small 
arrows). (B): ANP dogs showed strong TLR4 staining in the cytoplasm and 
nucleus of alveolar macrophages (dotted line arrow). There are also positive 
inflammatory cells in alveolar septal capillaries (small arrows)(C): Airway epithelial 
cells in control dogs showed a granular and irregular TLR4 staining whereas 
airway epithelial cells in ANP dogs showed different staining pattern of TLR4 such 
as apical staining as shown in (D)(airway staining indicated by arrow heads).  
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Figure 3.11.Immunohistochemical staining for IL6 in dog lungs. (A): 
Occasionally, alveolar macrophages were observed with nuclear staining 
(arrow) for IL6 in some of the control dogs (B): In half of ANP dogs, strong 
intracytoplasmic and intranuclear staining for IL6 was noted in numerous 
alveolar macrophages (arrows) and in mononuclear phagocytes in alveolar 
septa (dotted line arrows).  
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Figure 3.12.Immunohistochemical staining for iNOS in dog lungs. (A): 
Control dogs did not show any iNOS staining. (B): ANP dogs showed iNOS 
staining in the nucleus, cytoplasm or both in alveolar macrophages in some 
cases (arrows in B indicate stained alveolar macrophages) 
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Table G: Summary of immunohistochemistry for inflammatory markers in ANP and control dog’s lung 
  vWF TLR4 IL6 iNOS 
Alveolar 
macrophages 
Ctl : 0 % (0/6) ctl : 0 % (0/6) ctl: 50% (3/6) ** ctl : 0 % (0/6) 
ANP: 48% (10/21) ANP: 48% (10/21) ANP: 66% (14/21) ** ANP: 62% (13/21) 
Mononuclear 
phagocytes in 
septa 
Ctl : 0 % (0/6) ctl : 0 % (0/6) ctl : 0 % (0/6) ctl : 0 % (0/6) 
ANP: 76% (16/21) ANP: 86% (18/21) ANP: 62% (13/21) ANP: 0% (0/21) 
Vascular 
endothelial cells 
(med-large b.v.) 
Ctl : 100% (6/6) ctl : 100% (6/6) ctl : 0 % (0/6) ctl : 0 % (0/6) 
ANP: 100% (21/21) ANP: 86% (18/21) ANP: 0% (0/21) ANP: 0% (0/21) 
Vascular 
endothelial cells 
(capillary) 
Ctl : 0 % (0/6) ctl : 0 % (0/6) ctl : 0 % (0/6) ctl : 0 % (0/6) 
ANP: 95% (20/21) ANP: 19% (4/21) ANP: 0% (0/21) ANP: 0% (0/21) 
Airway epithelial 
cells 
ctl : 0 % (0/6) 
 
ANP: 0% (0/21) 
ctl : 100% (6/6) * ctl : 0 % (0/6) ctl : 0 % (0/6) 
ANP: 76% (16/21) * ANP: 0% (0/21) ANP: 0% (0/21) 
     
The percentage (%) refers to the percentage of dogs showing staining for each inflammatory marker. The numbers in 
parenthesis ( ) represent the absolute number of dogs showing staining over the total n number (n=6 for control dogs, 
n=21 for ANP dogs)  
* Indicated results for TLR4 staining of airway epithelial cells corresponds to the total number of dogs showing any 
pattern of epithelial cell staining. Refer to the text for the frequency of each type of epithelial staining (apical, basal, 
cytoplasmic) 
** Even if the % do not illustrate it, the IL6 staining of alveolar macrophages differed between control and ANP dogs in 
the nature of the staining and the number of positively staining alveolar macrophages.   
B.v.: blood vessels 
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Table H: Spearman rank correlation coefficients for different associations  
between the lungs and pancreas in ANP dogs.  
Lung variable 
(Dependant variable) Independent variable 
Spearman 
coefficient r (p 
value) 
Lung histology scores  Pancreas histology scores  0.18 (p=0.45) 
Lung histology scores  Pancreas necrosis scores 0.16 (p=0.49) 
Lung histology scores  Pancreas inflammatory cell scores 0.05 (p=0.81) 
Lung mononuclear 
phagocytes (MAC387) 
(Without outlier) 
Pancreas histology scores  0.34 (p=0.13) (0.41, p=0.07) 
Lung mononuclear 
phagocytes (MAC387) 
(Without outlier) 
Pancreas necrosis scores 0.17 (p=0.48) (0.35, p=0.13) 
Lung mononuclear 
phagocytes (MAC387) 
(Without outlier) 
Pancreas infiltration of inflammatory 
cells scores 
0.46 (p < 0.05) 
(0.49, p<0.05) 
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Figure 3.13. Spearman Rank correlations between lung inflammation and 
pancreatitis scores in ANP dogs. (A): Association between lung histology scores 
and pancreas histology scores. (B): Correlation between macrophages/monocytes 
positive with MAC387 antibody and pancreas histology scores. (C): Correlation 
between macrophages/monocytes positive with MAC387 antibody and pancreas 
necrosis scores and (D): Correlation between macrophages/monocytes positive 
with MAC387 antibody and pancreas inflammatory cell scores. The coefficient r 
value in parenthesis represents the r value after excluding the outlier value 
(indicated with the pointed circle). 
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 3.4 DISCUSSION  
 
Until now, there was only a single case report published in 1995 
describing lung histology of a 3 year old dyspneic miniature poodle dog with ANP 
(16). To my knowledge, I present the first evaluation of the lung histopathology of 
a group of clinical cases of dogs that suffered from ANP. This study includes 
histological and immunohistochemical data from 21 dogs that died or were 
euthanized with a diagnosis of ANP between the years of 2000-2013. The data 
show that although only 4/21(19%) dogs with ANP presented clear clinical 
evidence of pulmonary complications, most of ANP dogs showed histological 
signs of lung inflammation. In addition, immunohistochemical analyses showed 
significant infiltration of mononuclear phagocytes in the alveolar septa of the 
lungs of dogs suffering from ANP, which suggested that PIMs are induced in 
dogs suffering from ANP. Furthermore, increased levels of TLR4 and IL6 in lungs 
of ANP dogs were associated with the recruitment of PIMs and indicate the 
presence of acute lung inflammation.  There was also induction of iNOS in 
alveolar macrophages, which may be a protective mechanism occurring during 
ANP to prevent further lung injury. Finally, this study revealed that lungs of ANP 
dogs showed evidence of a strong microvascular response indicated by robust 
staining for vWF in endothelial cells of septal capillaries. The findings reported in 
this study are valuable as most of the knowledge about lung injury associated 
with AP comes from rodent models and this is the first time that lung 
inflammation in spontaneous cases of ANP in dogs is described. Furthermore, 
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this is the first study investigating the recruitment of PIMs in a large group of 
dogs presenting with clinical diseases. 
 
3.4.1 Clinical features of ANP dogs 
The medical records revealed that ANP dogs included in this study were 
mostly older dogs (median of 8 years old) of various breeds and with no sex 
predisposition. All ANP dogs were presented to the emergency with high 
morbidity and most of them died or were euthanized within 48 hours after 
presentation. All dogs that had CBC’s performed within 48 hours prior to death 
(n=14) showed inflammatory leukograms indicative of severe inflammatory 
processes and systemic inflammatory response syndrome. May be due to older 
age of the patients, we found high incidences of kidney diseases, including 
glomerulonephritis (38%) and glomerulosclerosis (14%), and liver diseases such 
as chronic hepatitis (19%) were recorded. Other concomitant conditions present 
included pre-existing diabetes mellitus (14%), diabetic ketoacidosis (9%) and 
various types of enteritis (24%). Clinical and pathological findings that could have 
been complications of ANP included peritonitis (38%), hepatic necrosis (24%), 
DIC (19%), renal tubular necrosis (9%), and duodenal necrosis (5%).  
The incidence of concomitant conditions/complications previously reported 
in two retrospective studies reviewing the medical records of 61 dogs with AP (2) 
include: pre-existing diabetes mellitus (6.6%), diabetic ketoacidosis (13%), 
peritonitis (59%), and coagulation abnormalities including DIC (11.5%), and for 
the second retrospective study of 80 AP dogs (5): pre-existing diabetes mellitus 
!! 72!
(36%), hepatopathy (21%), gastrointestinal disorders (5%) , leukocytosis and/or 
left shift (>10% band neutrophils) (91%) and DIC (4%). Even if the incidences of 
each concomitant condition may vary between studies, the main concomitant 
conditions and complications reported in those two retrospective studies 
correspond to my findings to suggest that ANP dogs in my study may broadly 
represent the dogs suffering from AP. The information collected from the medical 
records of dogs with ANP illustrate that various factors can be involved in the 
development of pulmonary complications during ANP. Although the influence of 
other clinical factors on the development of AP makes it challenging to interpret 
the results, such complexity makes the study stronger compared to rodent 
models. 
As for the clinical signs of pulmonary complications, the previous 
retrospective studies reported clinical evidence of dyspnea or tachypnea in 4/61 
AP dogs (7%) (2) and 18/80 AP dogs (23%) (5). In my study, I recorded that 4/21 
(19%) had pulmonary complications including 3 dogs with pleural effusion and 
one dog with only increased lung sounds upon auscultation. One dog with pleural 
effusion had dyspnea. The incidence of pulmonary complications reported in my 
study remains slightly lower than what is published for human patients with 
severe AP where the incidence of pulmonary complications range between 18-
46% (12-15). 
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3.4.2 Mechanisms of lung inflammation in ANP dogs 
The histological evaluation of the lungs of dogs that suffered from ANP 
revealed that most cases had signs of lung inflammation characterized by 
significant recruitment of monocytes and macrophages in alveolar septa, which 
was confirmed with immunohistological staining using MAC387 antibody. Unlike 
the data from most studies using rodent models of AP (64, 156, 159), the lungs 
from ANP dogs did not show recruitment of neutrophils in alveolar septa or 
alveolar spaces. The main purpose of this study was to assess the recruitment of 
PIMs in the lungs of ANP dogs although, as the MAC387 antibody detects both 
macrophages and monocytes, I cannot state that all of the MAC387-positive cells 
are macrophages. Also, the resolution of the light microscope does not lend itself 
to demarcate the septal interstitium from the septal capillary lumen to distinguish 
between interstitial versus the intravascular macrophages. However, considering 
that interstitial macrophages are much fewer in numbers and challenging to 
observe with a light microscope, I believe that most of the positive cells are PIMs.  
PIMs are now established critical regulators of lung inflammation in the 
species where they are normally present as well as those in which the PIMs are 
induced through physiological stress such as bacterial infections or liver 
dysfunction (111, 112). Dogs are one of the species that lack constitutive PIMs 
(118-120) and there has not been any investigation of PIM recruitment in dogs 
suffering from clinical diseases. The reason we need to understand whether 
PIMs are recruited in any systemic condition is the ability of induced PIMs to 
exacerbate inflammation in the lungs and to increase the mortality following 
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secondary microbial challenges (111). This is highly relevant regarding ANP 
patients as secondary gut barrier dysfunction leading to endotoxemia is a known 
complication in human patients (198, 199) and is often suspected clinically in 
dogs. Therefore, it is important to investigate the recruitment and function of 
PIMs in dogs suffering from ANP. 
As mentioned previously, lungs from ANP dogs showed reduced amount 
of neutrophils compared to control dog lungs. There are various explanations 
possible for this finding. It is possible that neutrophils are being massively 
recruited and sequestered into the pancreas during the early phase of ANP and 
therefore are not available to infiltrate the lungs. It is possible that activated cells 
in the lung during ANP do not produce chemokines such as MIP and IL-8, which 
attract neutrophils, but rather produce chemokines such as MCP-1 that recruit 
monocytes and macrophages. Also, ANP dogs may be euthanized after the 
phase where neutrophils are recruited to the lungs, which would occur in the 
early phase of ALI. As for the outlier case showing substantial numbers of 
neutrophils in the lungs it is possible that this case had another cause of ALI 
independent of ANP.  
A second major finding in this study is the robust staining for vWF in the 
alveolar septal capillaries in all ANP dogs compared to lack of staining in septal 
capillaries in lungs from control dogs. During inflammation or vascular injury, 
endothelial cells release the content of Weibel-Palade Bodies, which contain IL-8, 
P-selectin, and vWF (204, 205). It is known that a portion of the released vWF 
remains attached to the endothelial cell surface to allow adhesion of platelets 
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during initiating of the coagulation cascade (206). During ANP, pancreatic 
proteases including trypsin, elastase, and PLA2 are released into the blood 
circulation (149) and are capable of causing vascular injuries (149, 156-158). 
Therefore, one hypothesis for the presence of vWF in alveolar septal capillaries 
of ANP dogs would be that circulating pancreatic enzymes could activate and 
injure the lung microvasculature and induce the synthesis and release of vWF in 
an attempt to repair the damaged endothelium and prevent hemorrhage or 
increase in vascular permeability. The granular vWF staining on the capillary 
endothelial cells may be interpreted as localized accumulation of secreted vWF 
or clustering of blood-borne vWF. It was previously proposed in our laboratory 
that this granular vWF staining may be aggregation of platelets containing vWF, 
but dog platelets do not contain vWF as opposed to other species (207, 208). It is 
however possible that this type of staining corresponds to vWF-platelet 
complexes (209). I did not observe vWF staining in alveolar septal capillaries in 
control dogs possibly because vWF is only synthesized in those blood vessels 
during inflammation rather than in resting endothelial cells. A similar 
phenomenon was observed for the presence of IL-8 in Weibel-Palade Bodies 
where this chemokine was only present during inflammation and not in resting 
endothelial cells (210, 211).  
In addition to being involved in hemostasis, vWF has a direct role in 
inflammatory processes such as providing binding sites for leukocyte receptors 
including P-selectin glycoprotein ligand-1 (PSGL-1) and integrin-β2 and therefore 
promoting rolling and adhesion of leukocytes to the endothelium (212) (213). It 
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was also reported recently that vWF can bind to the cell receptor named Singlec-
5 present in various human immune cells including macrophages, which led to 
internalization of vWF in early endosomes (214). Although Singlec-5 is not well 
conserved between species, a similar mechanism could be occurring in dogs 
with ANP to clear excessive circulating vWF, which needs to be further 
investigated. This is interesting as intravascular mononuclear phagocytes and 
alveolar macrophages of a few of the ANP dogs showed cytoplasmic staining for 
vWF suggesting that vWF was internalized in those cells. Another suggestion 
that may be investigated to explain this finding could be that alveolar and 
intravascular macrophages simply bind to extra-cellular secreted vWF. Finally, 
expression of vWF in the lung microvasculature of ANP dogs may have indirect 
pro-inflammatory effects as it allows platelets to aggregate in the lungs and 
various inflammatory roles have now been attributed to platelets including 
facilitating leukocyte recruitment to the site of inflammation (215). The 
recruitment of platelets by vWF may also be one of the mechanisms for the 
recruitment of PIMs in the lungs of ANP dogs. 
Since endotoxin or bacterial translocation from the gut is a possible 
complication during ANP (198) (199), the expression of TLR4 in the lungs of ANP 
dogs was assessed with immunohistochemical staining. Staining for TLR4 was 
present in the airway epithelium, vascular endothelium of medium-large blood 
vessels, and occasional septal monocytes and alveolar macrophages of control 
dogs. The staining for TLR4 observed in control dogs corresponded to what was 
previously reported regarding TLR4 staining in normal lungs from cattle, pigs and 
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horses (216) (86) (134) (98, 217). In lungs of ANP dogs, TLR4 staining was 
localized in the numerous newly recruited mononuclear phagocytes, mostly PIMs, 
and alveolar septal capillaries and in alveolar macrophages of some cases. The 
TLR4 staining in PIMs has been shown in veterinary species including pigs, 
horses, and cattle (86, 134, 216) and role of PIMs in adding to the total amount of 
TLR4 mRNA in the lung was demonstrated through significant reduction in TLR4 
mRNA amount following depletion of PIMs (134, 135). The recruited septal and 
alveolar macrophages in dogs with ANP may increase the amount of total TLR4 
in the lungs, which would increase the susceptibility for endotoxin-induced lung 
inflammation as well as contribute to the release of excessive cytokines into 
circulation. Lungs of rats with acute haemorrhagic necrotizing pancreatitis have 
increased levels of TLR4 mRNA and protein (174). Interestingly, in contrast to 
the control dogs, some medium sized blood vessels and airway epithelium in 
ANP dogs did not show TLR4 staining. Similar observations were also reported 
in inflamed lungs from Mannheimia hemolytica-infected calves and Pasteurella 
multocida-infected Water buffalo (91)(216). The reason for this loss of TLR4 
expression in blood vessels and airway epithelium is not clear but could be a 
protective mechanism to reduce endotoxin-induced inflammtion of the infected 
lungs. 
To further assess the pro-inflammatory response in lungs of ANP dogs, 
immunohistochemistry for IL6 was performed, which is an important pro-
inflammatory cytokine produced during acute inflammation and during SIRS. 
Similar to the expression of TLR4, increased staining for IL6 was present in lungs 
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of ANP dogs most likely due to the recruitment of septal macrophages and 
activation of alveolar macrophages. This corresponds to the report of increased 
levels of IL6 along with TLR4 in the lungs of rats with acute haemorrhagic 
necrotizing pancreatitis (174). IL6 staining in septal mononuclear phagocytes 
suggests that PIMs are pro-inflammatory and participate in the production of pro-
inflammatory cytokines released in the systemic circulation during ANP. 
Finally, alveolar macrophages showed staining for iNOS in some ANP 
cases. The staining for iNOS is interesting as the study of the role of NO in ALI 
associated with experimental AP has led to contradicting results. Indeed, NO has 
been attributed both pro and anti-inflammatory effects during ALI associated with 
AP in rodent models (164) (140) (174). Although this is only speculation, the 
induction of iNOS in lung macrophages may constitute a protective mechanism 
against lung injury during ANP by promoting vasodilatation and preventing 
vascular congestion or occlusion of capillaries caused by formation of thrombi 
secondary to excessive expression of vWF in those blood vessels. However, the 
possibility that NO could cause oxidative stress and create further lung injury 
must also be considered. 
   
3.4.3 Correlation between lung inflammation and ANP severity 
 This study also assessed whether the severity of pancreatitis lesions had 
an effect on the recruitment of monocytes/PIMs in the lungs during ANP. The 
results showed that the amount of inflammatory cells infiltrating the pancreas 
(based on histological scoring) was moderately correlated to infiltration of 
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monocytes/PIMs in the lungs. Furthermore, the presence of inflammatory cells in 
the pancreas was correlated more to recruitment of monocytes/PIMs in the lungs 
than the presence of pancreatic necrosis lesions. This suggests that 
inflammatory mediators released by inflammatory cells present in the pancreas 
during ANP are more involved in the pathophysiology leading to lung injury than 
are the products released in the blood circulation by necrotic acinar cells.  
 
3.4.4 Limitations and flaws  
A larger study size for both control dogs and ANP cases could have 
helped to improve the statistical significance. The sample size for ANP cases 
was limited for two main reasons. First, not all ANP dogs’ owners agreed to 
perform a post-mortem examination on their dog. Second, not all ANP cases had 
both lung and pancreas tissues available in PDS. Although, to increase the 
sample size, 4 external cases were added to this study, but the complete medical 
records for those dogs were not available. As for control dogs, it was challenging 
to find healthy dogs with normal lung and pancreas that had to be euthanized. 
Although control dogs from the SPCA seemed visually healthy, we could not do 
clinical evaluation than a visual assessment to rule out presence of subclinical 
conditions in those dogs. 
As this study used retrospective clinical cases of ANP in dogs, various 
clinical factors may have varied among cases influencing the lung results and 
include the period of time between the ANP onset and death, treatments 
received during hospitalization such as anti-inflammatory drugs, analgesics, 
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diuretics and antibiotics and previous history of lung diseases. In addition, the 
presence of concomitant conditions/complications in the ANP cases was 
reported in this study but their effect on the lungs could not be assessed.  
Also, using tissue samples from retrospective cases brings the issues of 
variable sampling, fixation, and processing protocols, which can have 
consequences on the immunohistochemical staining quality causing inconsistent 
staining intensity among cases and making the interpretation challenging. In 
addition, since fixation of the lung in a clinical setting does not include instillation 
of fixative into the airways, the preservation of the lung morphology between 
cases varied resulting in different levels of atelectasis, which may have 
influenced the immunohistochemistry to some degree. The study design was 
also limited by the fact that very few antibodies are available for dog tissues and 
antibody with mouse or human specificity had to be tried and standardized. I also 
failed to find a specific antibody for macrophages that does not also bind to 
monocytes that would have been better to study the presence of PIMs, which 
however is a minor issue.  
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3.4.5 Conclusion 
Because there has been clinical evidence of pulmonary complications in 
clinical cases of AP in dogs, we sought to determine recruitment of PIMs in our 
study, and our data show significant recruitment of septal mononuclear 
phagocytes, mostly PIMs, in the lungs of dogs that suffered from AP. The 
interaction between expression of vWF in alveolar septal capillaries and the 
recruitment/adhesion of PIMs in the microvasculature of ANP dog lungs would be 
interesting aspect for additional studies. In addition, based on what we know 
about PIMs in other species, the increase in the number of PIMs along with 
increased expression of TLR4 in ANP dog lungs would increase their 
susceptibility for enhanced lung inflammation in response to exposure to further 
microbes or their products during the course of ANP. This could be one of the 
explanations for the higher incidence of pulmonary complications in humans than 
in dogs. Indeed, people with ANP are generally kept alive longer compared to 
dogs suffering from ANP, which are often euthanized earlier in the course of the 
disease because of significant abdominal pain or financial issue. Therefore, the 
longer clinical care of humans with severe AP is more likely to expose them to 
secondary lung challenges leading to exaggerated lung inflammation and 
respiratory distress. Overall, dogs suffering from ANP should be closely 
monitored for signs of respiratory complications, especially if they develop 
endotoxemia or if they are at risk of being exposed to secondary microbial 
respiratory challenges during the course of the hospitalisation.  
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CHAPTER 4: MOUSE MODEL OF ACUTE NECROTIZING PANCREATITIS  
4.1 Introduction 
 
Severe acute pancreatitis is a common condition in human patients with 
an annual incidence of 13-45/100,000 people (1) and also in dogs although the 
exact incidence is not known. Both people and dogs suffering from severe acute 
pancreatitis are at high risk of developing systemic inflammatory response 
syndrome and multiple organ dysfunction syndrome with mortality rates as high 
as 50% (2-4, 6-9). In human patients suffering from severe AP, it is well 
established that pulmonary complications are a major cause of death and can be 
responsible for up to 60% of the mortality occurring in the first week of the 
disease (10, 11). Furthermore, the incidence of ALI in people with AP varies from 
18%-46% (12-15) and clinical signs of respiratory complications in dogs are also 
reported in the literature (2)(5).Therefore, in the past decades, various studies 
using rodent models of severe AP have been conducted to attempt to describe 
the mechanisms involved in the development of ALI during severe AP. 
Lung injury reported in rodent models with severe AP mostly corresponds 
to changes characteristic of ALI including infiltration of neutrophils in the alveolar 
septa and alveolar spaces, presence of edema and, in some cases, hemorrhage. 
The cellular response during ALI is strongly modulated by the pulmonary resident 
macrophages including alveolar macrophages and interstitial macrophages. Thus, 
there are multiple studies evaluating the roles of alveolar macrophages in the 
development of lung injury associated with AP but no study to my knowledge 
assessed the induction of PIMs during experimental acute pancreatitis.  
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PIMs are highly phagocytic large cells (20-80 µm diameter) with 
characteristics of mature macrophages and are believed to have pro-
inflammatory functions. Some species have constitutive PIMs such as cattle, 
sheep, goats, horses, and pigs (97-104) (105-107) whereas other species 
including rats, mice and rabbits don’t have constitutive PIMs but have induced 
PIMs upon physiological stress such as endotoxemia and liver dysfunction(110) 
(101, 111, 112). Humans and dogs were also not shown to have constitutive 
PIMs (113, 118-120). Most of the studies show that activation of constitutive or 
induced PIMs would enhance the host susceptibility to lung injury during 
subsequent microbial challenges (111). 
Rodent models, mostly rats, of AP have been used to study mechanisms 
of inflammation in the pancreas and other organs associated with AP. ANP in 
rats and mice is induced through treatment with L-arginine. I observed that PIMs 
are recruited in the lungs of dogs suffering from ANP. Therefore, to understand 
the mechanisms of recruitment of PIMs and their contributions to ANP-
associated lung inflammation, I decided to establish a mouse model of ANP 
through injections of L-arginine followed by evaluation of their lungs at various 
time points. The objective of this study was to first characterize lung inflammation 
in a mouse model of ANP. The second objective was to determine whether PIMs 
are induced in a mouse model of AP.   
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4.2 Materials and methods 
 
4.2.1. Reagents 
L-arginine monohydrochloride (cat # 11039-100G) and endotoxin-free 
saline (S8776) used to make the L-arginine solution were purchased from Sigma-
Aldrich. The following reagents used in the MPO assay were from Sigma-aldrich : 
Cetylthrimethylammonium chloride (CTAC), 3’, 5, 5’- tetramethylbenzidine 
hydrochloride(TMB), myeloperoxidase (MPO) from human leukocytes (M6908-
5U). The DC Protein assay kit was from BIO-Rad. 
4.2.2. Animals 
Six to eight week old male C57BL/6 (19-27g) mice (n=30 for the final 
experiment, n=11 for the second pilot study and n=8 for the third pilot study) were 
purchased from Charles River Laboratories (Montréal, Québec, Canada), except 
for the mice used in the first pilot study (n=9), which were provided by Animal 
Resources of the University of Saskatchewan. Mice were housed individually in 
the Animal Care Unit (ACU) of the WCVM in standard shoebox cages in a 
controlled room with ambient temperature of 23oC +/- 2oC and a 12 hour light-
dark cycle. They were fed standard laboratory chow and had water ad libitum. 
The University of Saskatchewan Animal Research Ethics Board approved all 
procedures involving mice. 
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4.2.3. L-arginine-induced ANP mouse model pilot studies 
Three pilot studies were performed in order to standardize the L-arginine-
induced ANP mouse model. The sample size, time points, L-arginine solution 
concentrations, and posology for each pilot study are summarized in the 
Appendix II Table I. The two first pilot studies performed failed to induce 
pancreatitis. However, the third pilot study using a new L-arginine 
monohydrochloride product of higher purity (99.5% instead of 98%) and a 
different protocol led to the development of ANP. The protocol used in the third 
pilot study was designed with guidance from Dr. Rajinder Dawra from the 
Department of Surgery of the University of Minnesota, who generously 
suggested some modifications for my induction protocol based on his recent 
findings (not yet published). Dr. Dawra was the first to have used the L-arginine 
model in mice and has worked with this model since 2007 (175) (218). 
 
4.2.4 Standardized L-arginine-induced ANP mouse model protocol 
4.2.4.1 L-arginine monohydrochloride solution preparation 
A sterile L-arginine monohydrochloride 9% solution was prepared fresh on 
the day of the injection. First, 2250 mg of L-arginine monohydrochloride powder 
was mixed with 23 ml of sterile physiologic saline. The pH was adjusted to 7.0. 
Then, in a biosafety cabinet, saline was added to have a total volume of 25 ml in 
order to have a 9% L-arginine solution. The L-arginine solution was filtered with a 
syringe filter (0.2 µm pore, 25mm diameter) into a 30 ml sterile pharmaceutical 
sealed glass vial.  
!! 86!
4.2.4.2 L-arginine pancreatitis induction protocol 
The standardized protocol for the induction of ANP consisted of a first 
intraperitoneal (IP) injection of L-arginine solution prepared as described above 
at a dose of 4.5g/kg to each mouse. Mice were returned to their cage with access 
to food and water for one hour. Then, a second injection of the L-arginine 
solution was given at the same dose. Control mice received the same injections 
but with physiological sterile saline. The injections were done with 27G needles 
and 1 ml syringes. 
 
4.2.5 Experimental design 
4.2.5.1 Groups 
Mice were randomly divided into the following groups: control (n=9), 24 
hours ANP (n=7), 72 hours ANP (n=4) and 120 hours ANP (n=7). Control mice 
were divided to have three controls per time point. A mouse identification chart 
was first established to assign a number between 1-26 as follows: mouse #1-7 
(24 hour L-arginine group), mouse #8-10 (24 hour control group), mouse #11-14 
(72 hour L-arginine group), mouse #15-16 (72 hour control group), mouse #17-23 
(120 hour L-arginine group) and mouse #24-26 (120 hour control group). Then, 
mice were randomly assigned to each group, cage label cards were removed 
from the cages, numbered from 1-26, mixed as a deck of cards and put back on 
each cage, which randomly attributed a number to each mouse and therefore 
determined the treatment group. Only 4 mice were induced in the 72 hour L-
arginine treatment group during the final experiment because the results from 3 
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mice obtained during the pilot study #3 were combined with the data obtained in 
the final experiment to reduce the number of animals used. For the same 
reasons as for L-arginine treated mice in the 72 hour time points, only 2 control 
mice where present in the 72 hour time point group. 
 
4.2.5.2 Experiment timeline  
A timeline schematic is represented in the Appendix II figure 4.1 to 
facilitate the visualization of the experiment design. As shown in the schematic 
figure, to alleviate the challenge of handling a large number of animals on the 
same day, the L-arginine treatments were not done on all the animals on the 
same day. Furthermore, the L-arginine treatments on a group of mice on the 
same day were staggered by 35 minutes as it takes about 30 minutes to perform 
anaesthesia and the necropsy of one mouse on the day of the euthanasia. The 
mice receiving 2 injections of L-arginine as well as the control mice were also 
administered 2 injections of sterile physiological saline subcutaneously (SC) to 
prevent dehydration during the initial morbidity phase associated with the 
injections of L-arginine. The first injection of saline (1.5-2 ml) was administered in 
the scruff of the neck at the time of the second injection of L-arginine. Then, 3 
hours later (at t=4h) a second SC saline injection was given. An example of 
schedule followed on an induction day is illustrated in the Appendix II Table J. 
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4.2.5.3 Monitoring of animals 
It was noted during the pilot study #3 that significant morbidity and 
abdominal pain occur after the injections of L-arginine. Therefore, mice were 
monitored every hour for the first 8 hours following the injections of L-arginine 
and then, 3 times a day until the time of euthanasia. Briefly, mice were monitored 
for abdominal pain, weight loss, signs of respiratory distress, and lethargy. Mice 
were weighed every day to detect weight loss and a daily mean was calculated 
with the weight of every mouse present in each time point group to create a 
graph illustrating the weight loss pattern. No analgesic was used because of their 
potential effect on inflammation and development of pancreatitis (219) (220).The 
detailed monitoring parameters assessed are indicated in the Humane 
Intervention Point chart, Appendix II, Table K.  !
4.2.6 Sampling and processing 
4.2.6.1 Blood collection and euthanasia 
Mice were first anaesthetized with an intraperitoneal injection of a 
ketamine/xylazine mix (10:1) at the dose of 1-2% of body weight (0.3-0.6 ml for a 
30g mouse) followed by intra-cardiac puncture with a 25G needle to collect blood 
sample in a pre-heparinized (0.05 ml of heparin) 1ml syringe. Blood collection 
induced the death of the mice. Blood samples were kept on ice in an Eppendorf 
tube containing another 0.05 ml of heparin until they were sent to PDS clinical 
pathology laboratory for plasma amylase analysis and a CBC.  Blood could not 
be taken from one mouse belonging to the 24 hours L-arginine group as this 
mouse had coagulopathy at the time of euthanasia. In addition, the blood sample 
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from 2 mice (one in the control group and one in the 24 hour L-arginine group) 
clotted and could not be used for CBC, however plasma amylase activity could 
still be analysed. 
 
 4.2.6.2 Sampling of Pancreas 
After the mouse euthanasia, a laparotomy was performed to collect the 
pancreas rapidly to reduce the possibility of autolysis. The right lobe of the 
pancreas and the duodenum adjacent to it were kept in 4% paraformaldehyde 
overnight (16-20 hours) for paraffin embedding (see Appendix II Table L, for the 
complete protocol). At the same time, the other abdominal organs including the 
liver, kidneys, spleen, reproductive tract, bladder, stomach, and intestine were 
grossly evaluated for presence of abnormalities. The peritoneal cavity was also 
evaluated for evidence of peritonitis. The left lobe of the pancreas was snap-
frozen in liquid nitrogen for future experiments. 
 
4.2.6.3 Bronchoalveolar lavage (BAL) 
The BAL was performed only in the left lung. After thoracotomy and 
isolation of trachea, the right primary bronchus was ligated. Using small surgical 
scissors, a hole was made in the trachea to insert a small flexible cannula up to 
the tracheal bifurcation. The lavage was performed using 0.5 ml of cold sterile 
PBS pH 7.4 in a 1 ml syringe. The lavage was done 3 times in total. WBC count 
and cytospin for differential count was performed quickly after the BAL fluid was 
obtained. The remaining BAL supernatant was kept at -80oC for further analysis. 
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4.2.6.4 Lung sampling  
Before collecting the lungs, the left lung was perfused with 1 ml of 4% 
paraformaldehyde by gravity using a cannula inserted in the trachea. The right 
lung remained ligated to prevent entry of paraformaldehyde into it. The left lung 
was kept in 4% paraformaldehyde overnight (16-21h) for paraffin embedding. 
The processing protocol for paraffin embedding was the same as the one used to 
process the pancreas. The right lung was snap-frozen in liquid nitrogen to 
perform the lung MPO activity assay. 
.  
4.2.7 Pancreas histology grading  
In order to confirm the induction of ANP in the L-arginine treated mice, 5 
µm thick H&E stained sections of pancreas from all the mice were blindly 
evaluated and graded for pancreatitis lesions by an ACVP board-certified 
pathologist from the Department of Veterinary Pathology of the WCVM. The 
grading criteria were: 1) pancreatic necrosis 2) infiltration of inflammatory cells in 
the pancreas and 3) pancreatic edema. The type of inflammatory cells infiltrating 
the pancreas was also recorded. The scoring system is described in Table M. 
The summation of the scores obtained for each three grading criteria listed above 
generated the histology score.  
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Table M: Grading system used to evaluate mouse pancreas histology 
Grading 
criteria Score Description 
Pancreas 
necrosis 
0 Absence of pancreas necrosis 
1 Loss of zymogen granules only 
2 Necrosis in <10% of the pancreas parenchyma 
3 Necrosis in 10-25 % of the pancreas parenchyma  
4 Necrosis in 25-50 % of the pancreas parenchyma  
5 
Diffuse pancreas necrosis; >50% of the pancreas 
parenchyma 
Pancreas 
edema 
0 Absence of pancreas edema 
1 Focally increased space between lobules 
2 Diffusely increased space between lobules 
3 Pancreatic acini disrupted and separated 
Infiltration of 
inflammatory 
cell in the 
pancreas 
0 Absence of inflammatory cell infiltration in the pancreas 
1 Rare inflammatory cell or only around ductal margins 
2 
Inflammatory cell infiltration in the pancreas parenchyma 
(<50% of the lobules) 
3 
Inflammatory cell infiltration in the pancreas parenchyma 
(>50% of the lobules) 
Type of 
inflammation     Neutrophilic, monocytic, lymphocytic, mixed 
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4.2.8 Lung histology grading  
Lung sections from all the mice were graded for signs of inflammation by 
the same board-certified veterinary pathologist, who evaluated the pancreas. The 
evaluator was blinded as to the identity of the samples. Scores were attributed 
for 1) alveolar septa thickening and 2) the presence of lung edema. The type of 
inflammatory cells infiltrating the lungs was also recorded. The same scoring 
system as the one used to evaluate the lungs from AP dogs was used (Table C 
in Chapter 3). The summation of the scores obtained from both grading criteria 
provided the histology score.  
 
4.2.9 Lung immunohistochemistry for vWF and CD68  
The IHC was performed on mouse tissues following the same protocol as 
the one used on dog tissues (See section 3.2.7). The sections were incubated 
with pepsin to unmask antigens in the tissues. The following primary antibodies 
and dilutions were used: a polyclonal rabbit anti-human von Willebrand Factor 
antibody (P0448) (1:400 dilution in BSA1%) from DAKO and a polyclonal rabbit 
anti-human CD68 (Sc-9139) (1:25 dilution in BSA 1%) from Santa Cruz 
Biothechnology. The appropriate HRP-conjugated secondary antibody was 
diluted at 1:300 for the vWF staining and 1:100 for the CD68 staining. The color 
was developed for 3 minutes and the methyl green added to the slides for only 3 
seconds.  
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4.2.10 Lung CD68 cell count 
To assess the recruitment of monocytes/macrophages in the lungs of mice 
with ANP, lung sections from all the mice were stained with a CD68 antibody and 
the number of positive cells was counted in 10 fields of view at 400X following a 
consistent counting pattern. A field of view was considered appropriate for 
counting if more than 50% of the view was occupied by lung parenchyma. Fields 
of view where more than 50% of the area was occupied with airways (bronchiole) 
or blood vessels were ignored moving to the next field of view. Then, an average 
of the counts for the various groups (control, 24 hour, 72 hour and 120 hour) was 
done. 
 
4.2.11 Myeloperoxidase activity in mice lungs 
Lung samples equivalent to the size of 1/4th of a complete lung were 
homogenized in 0.5ml 50mM HEPES buffer solution at a pH of 8.0 in 2 ml 
homogenizing tubes containing 4 metallic beads (5mm diameter). Tissue 
samples were homogenized for 40 seconds in a tissue homogenizer. The 
homogenized samples were centrifuged at 1062g (10,000 rpm) for 20 minutes at 
4°C and the supernatants were discarded. The pellets were suspended in 0.5 ml 
0.5% cetylthrimethylammonium chloride (CTAC) and then homogenized and 
centrifuged again as described before. The supernatants were kept on ice until 
the MPO experiment was ready to be performed. For the standard MPO curve, 6 
twofold dilutions were prepared using MPO from human leukocytes diluted in 
50mM HEPES buffer solution, the same buffer used for the lung samples. The 
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standard curve was made with the following dilutions:  0.5 U/ml, 0.25 U/ml, 
0.125U/ml, 0.063 U/ml, 0.031 U/ml, and 0.016 U/ml. The lung sample 
supernatants were diluted 10x in phosphate citrate buffer in order to be included 
in the standard curve. MPO standards and lung samples were added to a 96-
wells plate with a peroxidase color substrate (TMB) for 2 minutes after which the 
reaction was stopped using 1M sulphuric acid. The optical density was measured 
using an optical reader at a wavelength of 450nm. After performing the MPO 
assay, a protein concentration assay was performed using the same samples 
that were used for the MPO assay. The protein assay was done using the BIO-
Rad DC Protein assay kit following the manufacture’s instruction. The results 
from the MPO experiment (U/ml) were divided by the samples’ protein 
concentrations (mg/ml) in order to have the final MPO results expressed in U/mg 
of protein.  
 
4.2.12 Statistical analysis 
Statistical analysis was performed using statistical software (GraphPad 
Prism, Version 5.04 for Windows, GraphPad Software, San Diego California 
USA). To detect differences among means of plasma amylase activity, a One-
way ANOVA on the ranked data was performed because of unequal variances 
(Bartlett) among groups. Then, Tukey’s multiple comparison was used as post-
hoc test. Histologic grading scores were expressed in medians with range and 
the comparison of medians among the 4 groups of mice was done by the non-
parametric test Kruskal-Wallis followed by Dunn's Multiple Comparison test as 
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post-hoc test. Results from the CD68 cell counts, CBC, BAL WBC and MPO are 
expressed in means ± standard error of the mean (SEM) and comparison of 
means among groups was done with One-way ANOVA (One-way analysis of 
variance) followed by Tukey’s multiple comparison as post-hoc test.  
 
4.3. Results 
4.3.1 Clinical signs in mice treated with L-arginine  
Immediately after receiving the first intraperitoneal injection of L-arginine, 
mice showed signs of acute abdominal discomfort (reduced mobility, rounded 
back, compulsively licking the abdomen, almond-shaped eyes, and ears 
flattened). After the second L-arginine injection, mice became more morbid and 
showed signs of tachypnea with superficial breathing and stayed morbid until the 
second subcutaneous injection of saline (3 hours after the second injection of L-
arginine) after which they began to recover slowly. It took at least 8-12 hours for 
the mice to become asymptomatic.  After the initial morbidity period and recovery, 
mice did not show signs of abdominal discomfort or signs of respiratory disease 
for the rest of the experiment up to the 120 hour time point. However, mice 
receiving L-arginine injections lost weight in the first 48 hours after which they 
began to regain weight but never regained their initial weight (Figure 4.2). The 
weight loss corresponded to approximately 5% of body weight (bw) in the first 24 
hours and to an additional 4% of bw between 24-48 hours. Control mice did not 
show any signs of abdominal discomfort, respiratory distress, and did not loose 
weight following the saline injections.  
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There was no unexpected mortality during this experiment. However one 
mouse in the 24 hour time point group never recovered fully and was 
hypothermic, had abdominal hemorrhagic effusion, and blood in the bladder at 
the time of necropsy. As pancreatitis was not severe at this time point, this 
complication was probably not related to pancreatitis but to an adverse reaction 
to L-arginine resembling a coagulopathy. 
 
4.3.2 ANP confirmation in L-arginine treated mice 
 
The mean values for the plasma amylase activity in each group of mice 
are as follows: control mice (1483 ± 48 U/L), 24 hour ANP mice (5528 ± 1210 
U/L), 72 hour ANP mice (6547  ± 1275 U/L) and 120 hour ANP mice (1399  ± 62 
U/L) (Figure 4.3). Compared to the normal plasma amylase values (obtained in 
the control mice), plasma amylase increased significantly 24 and 72 hours 
following the injection with L-arginine (p < 0.001). There were no differences in 
the plasma amylase activity in control mice and the 120 hour treatment group.  
The second indication of the presence of pancreatitis was the evaluation 
of the gross pathology of the pancreas at the time of the necropsy. Morphological 
changes were noted in the pancreas at each time point of the experiment (Figure 
4.4). Compared to the pancreas from the control mice, mice euthanized 24 hours 
post-L-arginine treatment showed an edematous and enlarged pancreas. At 72 
hour, the pancreas was discoloured (grey instead of pink) and enlarged with 
visually evident separations between pancreatic lobules whereas at 120 hour the 
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pancreas was atrophic allowing visualization of the left kidney, which is usually 
covered by the left lobe of the pancreas. 
The definitive diagnosis of ANP in mice injected with L-arginine was made 
with histological evaluation of the pancreas. Representative images of pancreatic 
histology are shown in Figure 4.4.  The histological evaluation of the pancreas of 
control mice resulted in scores of ’’0’’ for every scoring category leading to a total 
pancreas histology score of ‘’0’’ for every control mouse (n=9).  After 24 hours of 
the treatment, the pancreas showed a loss of zymogen granules in acinar cells 
but this did not lead to a statistical difference in total histology scores for this time 
point compared to the control group. The highest histology scores were obtained 
in the 72 hour treatment group where acinar cell necrosis affected greater than 
50% of the pancreas parenchyma. In addition, there was a massive infiltration of 
neutrophils between pancreatic lobules covering >50% of the parenchyma and 
pancreatic edema causing separation and disruption of acinar cells. All the 
observations made in the 72 hour group were significantly different from the 
control group (p<0.0001). The 120 hour group showed lesions similar to the 72 
hour group with no statistical differences between the histology scores obtained 
for these 2 groups. However, the presence of pancreatic edema in the 120 hour 
group was not statistically different from the control group. In addition, mostly 
lymphocytes instead of neutrophils were observed in the pancreas at 120 hour. 
The scores for each grading criteria and for each group of mice are summarised 
in Table N and illustrated in Figure 4.5. 
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As an indication for systemic inflammation, a CBC was performed on each 
mouse. The results for the CBCs are illustrated in Figure 4.6. White blood cell  
counts in control mice ranged from 2.8-7.9 x 109 /L (median 4.9 x 109 /L). 
Compared to the control WBC counts, there were no statistical differences with 
WBC counts for the various L-arginine groups using One-way ANOVA. However, 
there was a significant difference (p <0.05) between WBC counts for the 24 hour 
and 120 hour groups. In control mice, differential blood counts for neutrophils 
ranged from 0.2240-2.044 x 109 /L, and monocytes ranged from 0.0280 - 0.1720 
x 109 /L. There were no significant differences between the differential blood 
counts for monocytes or neutrophils in L-arginine groups and the control group. 
However, it is interesting to note that one mouse in the 24 hour L-arginine group 
showed neutrophilia whereas two mice in the 24 hour group and one mouse in 
the 72 hour group showed monocytosis, when compared to the other animals 
present in the respective groups (figure 4.6). 
 
 
4.3.3. Lung histology grading 
  
The lung histologic evaluation (Figure 4.7) revealed infiltration of 
mononuclear phagocytes in the lungs of mice in the 72 hour group only, which 
was significantly different (p < 0.001) compared to the control lungs. There were 
no noticeable histology changes in the 24 hour and 120 hour groups compared to 
the control mice lung histology.  
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4.3.4 Lung immunohistochemistry for vWF and CD68 
 
The vWF staining was used as a positive immunohistochemical control as 
well as a marker of inflammation.  Based on the qualitative evaluation, vWF 
staining was apparently increased in the lungs of L-arginine mice compared to 
control mice, as there was presence of granular staining in the alveolar septal 
capillaries of some ANP mice. Representative images of the vWF staining are 
shown in Figure 4.8. 
Representative images of the immunohistochemical staining with a CD68 
antibody and CD68 cell counts are shown in Figure 4.9. The CD68 counts 
(median; range) are as follows: for control mice (81; 55-147), for the L-arginine 
24 hour group (150; 115-190), for the L-arginine 72 hour group (190; 118-200) 
and for the L-arginine 120 hour group (135; 97-194). There was a significant 
increase in the number of CD68 cells in all mice treated with L-arginine (p < 0.01). 
However, there were no differences in the counts between the various L-arginine 
groups. Interestingly, it was noted in some mice that the staining for CD68 was 
located in the nucleus in addition to cytoplasms or only in the nucleus without 
cytoplasmic staining. For the purpose of counting positive cells, the cells were 
not differentiated for nuclear and cytoplasmic staining. However, qualitative 
evaluation indicated more nuclear staining for CD68 in mononuclear phagocytes 
in L-arginine treated mice compared to control mice. However, further detailed 
evaluation of the staining especially with the electron microscope would be 
necessary to confirm this observation.  In addition, staining for CD68 was present 
in the airway epithelial cells of both control and ANP mice, which was not 
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expected. Similar to the staining pattern of mononuclear phagocytes, presence of 
nuclear staining appeared more prominent in epithelial cells in lungs of L-arginine 
treated mice compared to controls. 
 
4.3.5 WBC counts in BAL fluid and total lung MPO activity 
The BAL WBC counts were not significantly different between control mice 
and the various L-arginine groups (p=0.08; Figure 4.10).  Cells present in the 
BAL fluid of all mice, including control and L-arginine treated mice, were 
mononuclear phagocytes only. The lung MPO activity also did not differ 
statistically between control and ANP mice (p=0.07; Figure 4.10).  
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Figure 4.2 Weight means for each group of mice at 24h post-injection 
intervals for L-arginine or saline (controls). 
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Figure 4.3 Plasma amylase activity (U/L) in control and L-arginine mice. There 
is a significant increase in plasma amylase at 24 and 72 hours following the 
injections of L-arginine compared to the control. Asterisks indicate significance 
different at p < 0.001. Mean values and SEM represented by horizontal line in 
graphs.   
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Figure 4.4 Gross anatomy and histology of the pancreas of control or 
L-arginine treated mice. (A-B): Control mice with normal pancreas (P) 
gross anatomy and histology. (C): Pancreas gross anatomy after 24h and 
(D): corresponding histology showing a loss of zymogen granules in acinar 
cells (arrows). (E): Pancreas gross anatomy after 72h and corresponding 
histology. F shows a massive infiltration of inflammatory cells, mainly 
neutrophils, between pancreatic lobules (inter-lobular space shown by 
asterisk) and acinar cell necrosis (dotted tail arrows). (G):  After 120h, the 
pancreas is atrophic and the left kidney (white asterisk) can be visualized. 
(H): Histology at 120h still shows acinar cell necrosis but lymphocytes and 
not neutrophils are being recruited in the pancreas.  
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Figure 4.5 Pancreas histology scores for control and L-arginine. (A): Scores 
for pancreas necrosis. (B): Socres for infiltration of inflammatory cells in the 
pancreas. (C): Scores for pancreas edema. (D): Pancreas histology scores: 
represent the sum of the 3 different scoring categories. Median values 
represented by horizontal line in graphs. Significant differences from control mice 
at p < 0.0001 denoted as asterisks (*). 
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Table N : Pancreas histology scores for the different grading criteria for control 
and L-arginine treated mice. 
 
 Control 24h L-arg 72h L-arg  120h L-arg 
Necrosis 0.0 1 (range 0-1) 4 (range 3-5)* 2 (range 1-5)* 
Inflammatory cells 0.0 0 (range 0-1) 2 (range 1-3)* 1 (range 1-3)* 
Edema 0.0 0 (range 0-1) 2 (range 1-3)* 1 (range 0-2) 
Histology score 0.0 1 (range 0-3) 8 (range 0-3)* 4 (range 2-10)* 
Data reported as median with range 
An asterisk (*) indicate a statistical difference with the controls at p<0.0001    
difference with controls. 
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Figure 4.6 CBCs results from L-arginine and control mice. 
(A): Results from the blood WCB counts. (B): Results from the blood 
differential counts for neutrophils. (C): Results from the blood differential 
counts for monocytes. There were no statistical differences between the L-
arginine groups and control group. However, the WBC count at 24h and 
120h were statistically different.  
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Figure 4.7  Lung histology and histology scores of control and ANP 
mice. (A): Lung sections from control mice showing normal histology. (B): 
Lung sections from 24 hour ANP mice with no significant changes. (C): 72h 
ANP mouse lungs showing increased cellularity (arrows) corresponding to the 
infiltration of mononuclear phagocyte cells in the alveolar septa (arrowheads) 
(D): 120h ANP mice with no significant changes. (E): Corresponding lung 
histology scores representing the sum of lung edema scores and alveolar 
septa thickening scores .(*) indicates p < 0.001. 
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Figure 4.8 vWF staining of mice lungs. (A): Representative image of vWF 
staining of sections of control mouse lung showing specific staining of blood 
vessels (arrows). (B): Lung sections from L-arginine mice showing granular 
staining in the alveolar septa (dotted tail arrows). 
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Figure 4.9 CD68 staining in control and ANP mice. (A): Lung section from 
a control mouse showing cytoplasmic staining of mononuclear phagocytes 
(arrows). Notice the absence of nuclear staining. (B): Staining of the lung 
section from a L-arginine treated mouse where mononuclear phagocytes 
show CD68 staining in the cytoplasm but also in the nucleus (broken tail 
arrow) (C): CD68 staining present in airway epithelial cells of control mice 
showing cytoplasmic staining and rare nuclear staining (D): CD68 staining 
present in airway epithelial cells of L-arginine mice showing cytoplasmic 
staining but also multiple epithelial cells with nuclear staining (E): Results 
from the CD68 positive cell counts for every mice group. (*) Indicates p < 
0.01.  
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Figure 4.10 Total WBC counts in BAL and lung MPO activity in control 
and ANP mice. (A): Results from the total WBC count present in the BAL 
fluid of control mice and mice in the different time point of ANP. (B): Results 
from lung MPO activity of control mice and mice in the different time point of 
ANP. The results from both assays were not statistically different compare to 
the controls. 
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4.4. Discussion 
I previously observed that septal mononuclear phagocytes, mostly PIMs, 
are increased in lungs of dogs that have died due to ANP. Since mice do not 
have constitutive PIMs similar to dogs, I decided to use a mouse model of ANP 
to examine the recruitment of PIMs during ANP in order to use the model to 
further understand the development of lung inflammation associated with this 
condition.  
Although rodent models, especially rats and not mouse, have been used 
to study ANP, it required three pilot studies to optimise the mouse model of ANP 
in our laboratory. The pilot studies were to establish an optimal protocol to induce 
ANP with intraperitoneal treatments of a L-arginine solution. The first pilot was 
based on the posology used in the rats!(40) and failed to induce ANP in mice. 
However, the second pilot study was based on the L-arginine-induced mice ANP 
protocol standardized by Dawra and colleagues (181) but did not lead to ANP in 
mice used in my experiment. The third pilot was based on personal 
communication with Dr. Dawra and resulted in ANP in my group of mice. The 
reasons for the failure to induce ANP in the second pilot study even after 
meticulously replicating every aspect of the published protocol including using 
the same strain of mice (C57BL/6) are unknown. One possibility is that L-arginine 
has been mainly used in rats to induce ANP and has only been used in mice 
recently and therefore it may require further standardization in mice.  
Clinically, mice treated with L-arginine only showed abdominal discomfort 
and lethargy in the first 12 hours following the injections of L-arginine. After this 
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period, mice did not show signs of discomfort or evidence of pulmonary 
complications even at the 72 hours time point, which is the period where more 
severe ALI has been reported in other studies using this model in mice (181, 184, 
185). The abdominal discomfort observed following the L-arginine injections may 
not be due to pancreatitis since only mild pancreatic lesions were present at 24 
hour post-injections. One hypothesis for the initial morbidity could include the rise 
in blood ammonia levels generated from the L-arginine catabolism following 
injections of L-arginine. Indeed, high levels of ammonia in the blood of rats 
receiving intraperitoneal injections of L-arginine were detected in the first 8 hours 
following L-arginine treatments (221). In addition, metabolic acidosis occurs 
following intraperitoneal administration of chloride salts of L-arginine reaching the 
most acidic urine sample values (pH=5.5-6.0) at 24 and 48 hours. Weight loss 
was noted during the first 48 hours following L-arginine, which could be 
associated with the initial morbidity period where food intake was significantly 
reduced. After the first 2 days, mice slowly regained weight suggesting that they 
were feeding normally again and had reduced physiological stress. CBC was 
performed on every mouse as an indicator for systemic inflammation. Although 
this was not statistically significant, the graph for the WBC counts suggested that 
leukopenia may occurs at 24 hours and 72 hours after receiving L-arginine 
injections, which suggest a systemic inflammatory response. A larger sample 
size may have increased the statistical significance for those results. It is also 
interesting to note that the blood neutrophils differential counts in the 72 hour L-
arginine group all corresponded to the lower-end values of the range for normal 
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neutrophils counts (based on the control neutrophils differential values) and is 
associated with the time point where massive infiltration of neutrophils occur in 
the pancreas. In addition, monocyte counts after 120 hours following L-arginine 
injections appeared to increase, but not significantly, and therefore it would be 
interesting to assess the recruitment of those cells in the lungs past this time 
point to see if more PIMs would be present in the lungs.   
The criterion used to confirm ANP in my experiments including plasma 
amylase levels and grading of pancreatic histology corresponded to the data 
published in other studies using the L-arginine induced ANP in mice (175)(184, 
185, 222). Although ANP was induced in the mice, there was a lack of neutrophil 
infiltration into the lungs based on histological evaluation and MPO activity assay. 
Lung inflammation characterized by neutrophils accumulation in ANP models has 
been reported previously (175)(184, 185, 222). The reasons for this discrepancy 
are not clear. One of the reasons could be that if L-arginine treatment induced 
ALI, I may have missed the optimal time point to detect the increase in 
neutrophils in the lungs. However, the peak of neutrophil infiltration reported in 
other studies using this mouse ANP model was at 72 hours (181, 184, 185), 
which was a time point included in my study design, therefore suggesting that 
neutrophils were simply not recruited into the lungs of L-arginine mice in my 
experiments. This creates a discrepancy, which needs to be resolved with further 
studies focusing on the recruitment of neutrophils in the lungs of animals 
suffering from ANP. It is interesting that the evaluation of lungs from ANP dogs 
also showed lack of neutrophil accumulation.  
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In addition to the quantification of neutrophil accumulation in the lungs, I 
also used vWF staining as a marker of vascular inflammation. The expression of 
vWF was increased in the mice in the L-arginine group as shown by more 
staining present in the alveolar septal capillaries. Similar to observations in lungs 
of ANP dogs stained for vWF, ANP mice showed granular staining in alveolar 
septa. As mentioned for the dog study, increased inflammation or vascular injury 
can lead to activation of endothelial cells and to the release the content of 
Weibel-Palade Bodies, which contain vWF. (204, 205). In another study, plasma 
levels of trypsin increased as early as 24 hours after the L-arginine treatments 
and continued to increase till 120 hours of the treatments (181). Therefore, since 
trypsin has been shown to cause vascular injury to various organs during AP 
including the lungs (156, 157), it is possible that this pancreatic enzyme injured 
vascular endothelium and increased expression of vWF in my study. The 
granular pattern of vWF staining on the capillaries endothelial cells may be due 
to focal accumulation after its secretion by the endothelium or clustering vWF 
present in the capillaries lumen. This staining could also be platelets containing 
vWF as mouse platelets contains vWF in their α-granules (223). The role of vWF 
in lung inflammation associated with ANP in mice or in dog patients is not clear 
however it could promote leukocytes adhesion, including PIMs, as both vWF 
alone or vWF-platelet aggregation on endothelial cells were shown to facilitate 
leukocytes recruitment to the site of inflammation (212, 213, 215).  
The main focus of my study was to evaluate whether L-arginine treatment 
would induce PIMs to make an argument for their use to study the role of PIMs in 
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ANP-induced lung inflammation and systemic pathophysiology. My data showed 
accumulation of CD68+ monocytes/macrophages in mice treated with L-arginine 
compared to the control mice at all the L-arginine treatment time points. However, 
there were no differences in the PIMs numbers between each of the L-arginine 
groups.  CD68 recognizes a lysosomal-associate membrane protein, which is 
more prominently expressed in differentiated macrophages (224). Therefore, 
CD68 provides cytoplasmic staining in reactive macrophages. However, I was 
intrigued by the nuclear staining for CD68 not only in septal macrophages but 
also in the airway epithelium, which also intensely reacted with the CD68 
antibody. The staining of the epithelial cells in various organs has been reported 
previously but the significance of such staining is not known (224). While the 
significance of nuclear staining for CD68 is not known, the staining appeared to 
be more prominent in L-arginine-treated mice compared to the controls. 
Nevertheless, the data show significant recruitment of CD68 septal macrophages, 
suggesting they are PIMs.  
 
4.4.1 Limitations and flaws 
The use of the L-arginine ANP model to assess the mechanisms involved 
in lung inflammation associated with this disease can raise some questions. As 
mentioned previously, L-arginine is a precursor for the production of NO by iNOS, 
which can be induced in alveolar macrophages (164, 171, 173). Therefore, in 
theory, L-arginine reaching the lungs via the systemic circulation could have 
direct protective or detrimental effects on the lungs via the production of NO by 
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alveolar macrophages. However, the reported half-life of 1-2 hours for L-arginine 
in mice (175) and its direct effect would likely lead to histological changes in the 
lungs earlier than 72 hours after the injections of L-arginine; however, that was 
not the case in my experiments. This observation combined with the fact that 
injury to abdominal organs other than the pancreas was not present in previous 
studies using the L-arginine model (180-182) argue in favour of selective and 
direct actions of L-arginine on the pancreas. 
The mice receiving L-arginine developed ANP but did not show clinical 
sign or mortality associated with ANP. This is at variance with the clinical disease 
where dogs and people suffering from ANP show high mortality and morbidity. 
Therefore, the mouse model despite its usefulness to evaluate the basic 
mechanisms of ANP may not model the real clinical disease.  
A larger sample size in each group could have improved the statistical 
significance of most results. Because inducing ANP in a group of 30 mice on the 
same day is technically impossible with the induction schedule that I followed, I 
had to induce ANP on three days. Therefore, the L-arginine solution had to be 
made three times and therefore the solution could have varied in concentration 
and pH slightly.  
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4.5. Conclusions  
Taken together, L-arginine induced ANP in mice and was associated with 
vascular inflammation in the lungs of affected mice as indicated by increased 
expression of vWF and accumulation of PIMs. The absence of neutrophils 
infiltration in the lungs of L-arginine mice as opposed to findings from other 
studies using this model is intriguing and questions the reproducibility of this 
model. Nevertheless, the lung changes observed in this mouse model of ANP 
corresponded well to the findings of recruitment of PIMs but not neutrophils and 
increased vascular expression of vWF in ANP dogs. Also, the use of L-arginine 
to induce PIMs in mouse provides a non-invasive and progressive method to 
study the recruitment of PIMs and the lung changes associated with ANP. 
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CHAPTER 5:  GENERAL DISCUSSION AND FUTURE WORK 
 
I report the first detailed investigation of the lung inflammation in clinical 
cases of ANP in dogs and conducted the first study assessing the induction of 
PIMs in a mouse model of ANP. The results showed that clinical cases of ANP in 
dogs develop lung inflammation during the disease. In addition, my work to 
establish a mouse model of ANP provides the first model to study the role of 
PIMs in ANP-associated lung inflammation and systemic pathophysiology in 
humans and dogs. The findings from this study show vascular inflammation and 
induction of PIMs in the lungs of animals suffering from ANP. Both dogs and 
mice are species lacking constitutive PIMs and therefore the mechanisms 
leading to their induction and adhesion to the lung microvasculature will be 
important to further characterize and understand. This study also brings the 
hypothesis that the activated pulmonary microvasculature through vWF 
expression could provide a favourable environment for PIMs to be induced and to 
adhere to the vascular endothelial cells. 
The appearance of PIMs as central characters in the pathogenesis of lung 
inflammation is changing the way we understand lung disease. While alveolar 
macrophages have been traditionally attributed the role of an conductor of pro-
inflammatory signals in the lung, the recent novel study of direct visualization of 
the role of alveolar macrophages in an isolated lung casts a serious doubt on 
such a rule (90). It is possible that while PIMs are induced and take over the pro-
inflammatory role, the alveolar macrophages provide signals to dampen the 
inflammation and take over the clearance of cell debris. The role of induced PIMs 
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has only been studied in the context of liver dysfunction through the use of rodent 
models of bile-duct ligation (111) or in septic rats (112). Those data suggested 
that PIMs make the host already suffering from liver dysfunction or sepsis more 
susceptible to endotoxin-induced lung inflammation and mortality(111). The 
possibility that induced PIMs in humans and dogs with severe AP could increase 
their susceptibility to subsequent respiratory challenges may be a key 
explanation for the respiratory distress occurring during the course of this 
disease. This is relevant as patients suffering from ANP are at risk of being 
exposed to further respiratory challenges either from air-born infections 
associated with hospitalization conditions or via the blood systemic circulation if 
gut barrier dysfunction occurs causing endotoxemia or septicemia. Therefore, a 
special attention should be made to prevent secondary microbial insults in 
patients with ANP during the course of the hospitalization.  
As for the future work, the mouse ANP model provides us a tool to study 
lung response to a secondary challenge following the onset of ANP through 
administration of endotoxins or bacteria, which would simulate what happens in 
clinical cases of AP complicated with dysfunction of the gut barrier. In addition, 
the role of PIMs in ANP-associated lung pathophysiology could be assessed 
through their depletion with gadolinium chloride or by the use of specific gene-
knockouts to study the molecular mechanisms such as the role of MCP-1 in the 
induction of PIMs. Finally, evaluating the lungs from human patients that suffered 
from severe AP in comparison to the findings in ANP dogs’ lungs would be very 
intriguing. 
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APPENDIX I 
 
 
Table A : Paraffin embedding protocol for dog’s lung and pancreas tissue. 
Solution Time period 
70 % ethanol, 37°C 1 h 
70 % ethanol, 37°C 1 h 
80 % ethanol, 37°C 1 h 
95 % ethanol, 37°C 1 h 
100 % ethanol, 37°C 1 h 
100 % ethanol, 37°C 1 h 
100 % ethanol, 37°C 1 h 
Xylene, 37°C 45 min 
Xylene, 37°C 45 min 
Paraffin, 60°C 30 min 
Paraffin, 60°C 10 min 
Paraffin, 60°C 10 min 
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APPENDIX II 
Table I: Summary of the mouse L-arginine ANP model pilot study experimental 
designs 
 Sample size 
Time 
points 
L-arginine solution Posology 
Pilot #1 
L-arginine group: 
 
• 2 mice per time point 
• Total of 8 mice 
 
Control group:  n=1 
6h 
48h 
72h 
120h 
L-arginine monohydrochloride 
in saline 10 % pH 7.4 
 
Product: A5131 Sigma Aldrich 
(purity 98%) 
1 IP injection 
Dose: 5g/kg 
Pilot #2 
 
L-arginine group: 
 
• 2 mice per time point 
• Total of 8 mice 
 
Control group:  n=3 
 
6h 
24h 
72h 
120h 
L-arginine monohydrochloride 
in saline 8 % pH 7.4 
 
Product: A5131 Sigma Aldrich 
(purity 98%) 
2 IP 
injections, 
1hour apart 
 
Dose: 4g/kg 
 
 
Pilot #3 
 
L-arginine group:  n=4 
 
 
Control group:  n=4 
 
72h 
L-arginine monohydrochloride 
in saline 9 % pH 7.0 
 
Product: 11039 Sigma Aldrich 
(purity 99.5%) 
2 IP 
injections, 
1hour apart 
 
Dose: 
4.5g/kg 
 
 
  
!!
122!
Figure 4.1: L-arginine ANP mouse model experimental design 
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TABLE J: Example of the L-arginine ANP induction schedule for one day    
Mouse # tx Time 1st 
injection 
Time 2nd 
injection + 
SALINE S.C. 
Time of 2nd 
SALINE 
S.C. 
1 L-arg 7h05 8h05 11h05 
2 L-arg 7h40 8h40 11h40 
3 L-arg 8h15 9h15 12h15 
4 L-arg 8h50 9h50 12h50 
5 L-arg 9h25 10h25 13h25 
6 L-arg 10h00 11h00 14h00 
7 L-arg 10h35 11h35 14h35 
8 SALINE 11h10 12h10 15h10 
9 SALINE 11h45 12h45 15h10 
10 SALINE 12h20 13h20 15h10 
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Table K: Human Intervention Point monitoring parameters used to monitor ANP mice 
 
 
Humane Intervention Point Monitoring Parameters 
 
Protocol 20100090: Lung inflammation associated with acute pancreatitis  
 
Mice will be observed every hour during the first 8-10 hours after the second injection of 
L-Arginine.  Thereafter, mice will be observed 3 times a day until euthanasia 
Time points : 24h, 72h, 120h 
  
Humane Intervention Point Monitoring Parameters 
 
Body Weight – weight the mice every 12 hours 
Score  0     Normal 
           1    <10% of loss of weight 
           2     10-15% of loss of weight 
           3    >15% of loss of weight 
Physical Appearance 
Score   0    Normal 
            1    Lack of Grooming, Orbital tightening: moderate, Ear position: moderately back 
            2    Rough Coat, Orbital tightening: severe, Ear position: severely back, round    
back 
            3    Very Rough Coat, grimace scale: severe, decubitus (ventral or lateral) 
Unprovoked Behaviour 
Score   0    Normal 
            1    Minor Changes :  
            2    Reduced Mobility, Decreased Alertness, ataxia 
            3    Self Mutilation, Immobility, Comatose 
Respitory pattern 
Score   0    Normal 
            1    increased respiratory rate, superficial  
            2    decreased respiratory rate and amplitude  
            3    intense respiratory efforts 
 
- An individual score of 2 in any category: Re-check variables every 2 hours. 
- If more than 2 categories are scored at 2 (or more): Consultation with Vet. is advised.*  
- An individual score of 3 in any category: Euthanize animal**.  
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Table L: Paraffin embedding protocol for mice lung and pancreas tissue. 
 
Solution Time period 
70 % ethanol, 37°C 1 h 
70 % ethanol, 37°C 1 h 
70 % ethanol, 37°C 1 h 
80 % ethanol, 37°C 1 h 
95 % ethanol, 37°C 1 h 
100 % ethanol, 37°C 1 h 
100 % ethanol, 37°C 1 h 
100 % ethanol, 37°C 1 h 
Xylene, 37°C 30 min 
Xylene, 37°C 1.5 h 
Paraffin, 60°C 30 min 
Paraffin, 60°C 1 h 
Paraffin, 60°C 2.5 h 
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